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Photoactivation Strategies for Therapeutic Release in
Nanodelivery Systems
Seok Ki Choi
Control of therapeutic release constitutes one of most critical aspects
considered in the design of nanoscale delivery systems. There are a variety of
cellular factors and external stimuli employed for release control. Of these,
use of light offers various photoactivation mechanisms that enable to
effectively engage in therapeutic release. It also allows a higher degree of
spatial and temporal control. Over recent decades, the application of
photoactivation strategies has seen remarkable growth and made a significant
impact on rapid advances in the field of drug delivery. This Review aims to
summarize the fundamental concepts and practical applications
demonstrated recently in numerous therapeutic areas from cancers to
infectious diseases. Its scope is defined by a focus on those photoactivation
strategies that occur via either linker cleavage, nanocontainer gating, or
disassembly. Each of these is discussed with specific examples and
underlying mechanisms that comprise linker photolysis, photoisomerization,
photothermal heating, or photodynamic reactions with reactive oxygen
species. In summary, this Review provides an inclusive summary of new
developments and insights obtained from recent progress in photoactivation
strategies and their applications in therapeutic nanodelivery.
1. Introduction
Designing a nanoscale system for effective therapeutic delivery
involves considerations in two primary aspects.[1–3] First, it relates
to how to incorporate a mechanism of cell targeting. This relies
on either passive infiltration (targeting) such as via the enhanced
permeation and retention effect in tumors[4] or active targeting
by binding to a specific biomarker or receptor.[5,6] This targeting
aspect has been extensively reviewed elsewhere,[3,5,7–10] and it is
beyond the current scope. Second, it relates to developing a re-
lease strategy by which the payload carried in a nanoscale system
is released or activated in a precisely controlled manner in the
cells or tissues ofinterest.[11] This involves incorporating aspecific
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mechanism of controlled release or ac-
tivation for its payload such as a drug
molecule, a therapeutic gene, or an effec-
tor molecule.[11–13] Many existing systems
utilize release strategies that are activated
conditionally under the influence of cellu-
lar factors or in response to pathophysi-
ological stimuli.[11] However, compared to
such passive strategies, there are externally
stimulated release strategies that are acti-
vated in a more controlled manner by ap-
plying light irradiation, sonication, or under
a magnetic field.[11] Of these, the photoacti-
vation strategy, a term which refers to light-
controlled drug activation or release here,
has attracted significant attention because
of its greater degree of precision in spa-
tial and temporal control.[11,14–16] It also of-
fers both photophysical and photochemical
mechanisms that are highly tunable for var-
ious delivery purposes.[11,14–16] This is evi-
dent with an exponential growth of its ap-
plications that contributed to advances in
the development of nanodelivery systems.
Photoactivation strategies are dividable primarily into three
modes, linker cleavage, disassembly and gating, each enabling a
payload release. This grouping is arbitrarily made on the basis of
their underlyingmechanisms that include linker photolysis, pho-
toisomerization, photodynamic reaction, or photothermal activa-
tion as validated in numerous release systems (Figure 1).[11,16–19]
First of all, linker photolysis plays a prominent role in drug re-
lease. Its use is also validated in the field of photocaging,[20,21]
a prodrug approach in which a payload molecule is inacti-
vated through its covalent conjugation to a photocleavable linker
(photocage).[22] This caged payload remains temporarily inac-
tive until its cage is detached through linker photolysis by light
irradiation.[23,24] Second, photoisomerization refers to a photo-
chemical process in which light triggers a molecular isomeriza-
tion that can lead to changes in its conformation, shape or even
pharmacological activity.[25,26] This mechanism plays a key role
in the control of gating by a drug-loaded nanocontainer through
its ability for modulating the gate size and shape.[27] Third, pho-
toactivation involves using a photosensitizer (PS) molecule[28]
and photoactive nanomaterial,[29,30] each having ability to pro-
duce reactive oxygen species (ROS)[31] upon light stimulation.
Due to its high chemical reactivity, ROS is able to engage in
various release mechanisms via either oxidative linker cleavage,
nanocontainer fragmentation or disassembly.[32] However, this
ROS-mediated release needs to be distinguished from photody-
namic therapy (PDT),[19,33–35] a therapeutic modality based on the
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induction of cytotoxicity via ROS-specific cellular damages.[31]
Last, photoactivation is achieved by using a class of photothermal
agents that display ability to produce a localized heat through sur-
face plasmon excitation by light.[36,37] This light-induced hyper-
thermia is normally employed in photothermal therapy (PTT),
a treatment modality that relies on induction of cytotoxicity by
hyperthermia.[18,36,38–41] However, heat production occurs strong
enough to induce physical alterations as well such as nanocon-
tainer disassembly or pore opening. Thus photothermal activa-
tion serves as an important mechanism for release strategies.
Recently, application of photoactivation strategies has played
an increasingly crucial role in the development of delivery
systems.[11,13,42–46] Considering their rapid growth and therapeu-
tic relevance, it would be of significant value to evaluate their con-
tributions made over recent 10 years. Here, this review article is
therefore interested in compiling their specific examples and dis-
cussing their releasemechanisms, design concepts, and practical
impacts. In its scope, this article is focused on topics of relevance
to release strategies based on linker photolysis, bond isomeriza-
tion, ROS production, or localized heating. However it excludes
applications solely based on PDT[19,33–35] and PTT[16,36,38–40] as
these have been extensively reviewed in numerous articles pub-
lished elsewhere as cited. Instead, it includes release strategies
associated with dual mode therapies enabled by PDT or PTT. In
its early contents, this article begins with comparing cellular fac-
tors versus noncellular stimuli involved in release controls, and it
provides an overview for photoactivation mechanisms, photoac-
tive nanoparticles (NPs) and photoresponsive linkers. These early
contents constitute a fundamental backbone to specific release
systems discussed in main topics later. In summary, this arti-
cle presents emerging concepts, developments, and challenges
in the application of photoactivation systems for therapeutic de-
livery.
2. Control Factors in Therapeutic Release: Cellular
versus Light Stimuli
In drug delivery systems, numerous types of chemical, enzy-
matic, or pathophysiological factors play a role in the control of re-
lease mechanisms. These involve drug-linker hydrolysis that oc-
curs in subcellular compartments such as acidic endosomes (pH
5.0–6.0)[47] and lysosomes[48,49] where drug-loaded NPs are tem-
porarily retained after their receptor-mediated endocytosis.[50,51]
Similarly, drug release occurs by linker hydrolysis under spe-
cific pathophysiological conditions such as tumor hypoxia (lower
oxygen),[52] low pH in extracellular matrices,[53] and enzyme up-
regulation in tumor-specific matrix metalloproteinase.[54–56] Re-
dox enzymes overexpressed in tumors[50,57] also contribute to re-
lease mechanisms by engaging in reductive cleavage of special-
ized linkers made of indolequinone[52] and nitroheterocycle.[58]
Elevated levels of glutathione and thiols in tumor cells[59] also
engage in facilitating the rate of disulfide drug-linker cleavage
through thiol-disulfide exchange.[60] Collectively, these cell-based
mechanisms occur passively under the condition dictated by cer-
tain microenvironmental or pathophysiological factors.
Unlike cellular or physiological stimuli, light application al-
lows an active control in therapeutic release. Its higher degree
of spatiotemporal control enables the occurrence of therapeu-
tic activation primarily at or near a targeted tissue within a de-
fined time frame.[11,29,61,62] This can offer a greater resolution
than other types of external stimuli investigated as active mech-
anisms in drug delivery such as ultrasound or magnetic field
stimulations.[63,64] Thus application of photoactivation strategies
offers potentially great benefits in delivery systems.[11,14,18,65,66]
3. Building Blocks in Photoactivation Delivery
Systems
A delivery system designed for photoactivation consists of three
main elements that include a drug molecule, a linker, and a
nanocarrier. The linker plays a role in not only drug attach-
ment but also providing a release mechanism. The nanocarrier
provides a physical space and method for drug loading which
occurs through either noncovalent encapsulation or covalent
attachment.[11] Additionally, the nanocarrier itself has a photoac-
tive property applicable for photoluminescence, photothermal,
or photodynamic activation.[16,19,29,34] Several classes of nano-




Photothermal nanomaterials refer to those that are able to pro-
duce a localized heat through plasmonic activation.[16,29,30,69–71]
These comprise of nanogold (Au) and nanosilver (Ag) that exist in
various shapes such as spherical gold NP (AuNP),[68,70,72,73] gold
nanorod (AuNR),[70] hollow gold nanosphere (HAuNS),[41,74–77]
and porous gold nanocage (AuNC).[69,78,79] Their photothermal
activation occurs by irradiation at a visible (vis) and near infrared
(NIR) region (500–800 nm). The produced heat rapidly dissi-
pates, causing a localized hyperthermia which is potent enough
to kill cells in a close proximity.[80,81] Besides these functional
properties, certain types of nanogold such as HAuNS[41,74,75,77]
and AuNC[78,79,82] offer unique structural benefits for drug de-
livery based on tunable cavities for drug loading and large sur-
face areas available for ligand conjugation. This is illustrated
with tumor targeted applications using HAuNS conjugated with
folic acid,[83,84] RGD peptide,[41] tumor-specific aptamer,[76] or
anti-EGFR antibody,[74] and AuNC conjugated with anti-HER2
antibody.[82] Such PTT application has proven effective for the
treatment of tumors[41,85] and antibacterial infections.[64,86]
3.1.2. Photodynamic Nanomaterials
Photodynamic nanomaterials[30,34,87] refer to those with ability
to produce ROS[31] that comprise of singlet oxygen (1O2), free
radicals (·OH, ·OOH, ·NO) and superoxide anion (·O2
−).[88]
These include graphene oxide (GO) nanosheet,[89–91] car-
bon nanotube,[92,93] TiO2 nanosphere,
[70,87] and semiconductor
quantum dots (QDs).[94] Their mechanism for ROS produc-
tion involves generation of either photoexcited electrons or
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Figure 1. A schematic description for photoactivation strategies applied for payload release in a receptor-targeted nanodelivery system. Each of these
strategies (linker cleavage, disassembly, gating; right) is enabled by either A) linker photolysis, B) photoisomerization, photoinduced production of
reactive oxygen species (ROS) for C) ROS-mediated photodynamic effects, D) plasmonic photothermal activation, or their combination.
electron-deficient holes that engage in an energy transfer reac-
tion with molecular oxygen (3O2) or water molecules near the
surface.[95,96] ROS production is also catalyzed by NP-loaded PS
molecules such as chlorin e6,[97] rose Bengal (RB),[64] and pro-
toporphyrin IX (PPIX).[98] Light activation for ROS production
occurs by one-photon absorption of UV[99] and vis light[95,96] or
two-photon absorption using a focused NIR laser.[96]
3.1.3. Upconversion Luminescent Nanomaterials
Use of NIR-responsive nanomaterials has made a signif-
icant impact on expanding the scope of photoactivation
strategies.[89,100–103] These include rare earth element-based up-
conversion nanocrystals (UCNs) such as NaYF4 doped with
lanthanide ions (Yb, Er, Tm).[89,101,102,104–106] UCNs show ex-
citation by NIR irradiation at 980 nm or 808 nm, which is
then upconverted for luminescence emission in shorter UV–vis
bands.[89,101,102,104,105] This NIR excitation is of great benefit be-
cause it belongs in the first biological window for optical imaging
(I-BW), which tends to scatter less and penetrate deeper than UV
or vis light.[107,108] UCN luminescence at UV–vis bands is highly
useful for applications in photoactivation because of its tunabil-
ity in wavelength (340–360 nm; 450–475; 540–560 nm),[105,109,110]
and strong intensity enough for triggering linker photolysis, ROS
production, or photothermal activation.[104] Besides lanthanide-
based UCNs, there are only few other NPs identified for upcon-
version luminescence that include bismuth ferrite (BiFeO3) and
lithium niobate (LiNbO3).
[111,112] Each of these also shows simi-




Photoresponsive linkers refer to those that are able to engage in
linker cleavage or alteration via either photolysis,[113] oxidative
fragmentation by 1O2 reaction,
[32,114–117] photoreduction,[118,119]
or photoisomerization.[25,120] As summarized in Figure 2, these
linkers comprise of several types that include ortho-nitrobenzene
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Figure 2. Types of photoresponsive linker used in photoactivation systems that are divided in to photocleavage (box) and photoisomerization (azoben-
zene, coumarate).
(ONB),[121–125] thioacetal ortho-nitrobenzene (TNB),[126]
coumarin,[122,125,127,128] 1O2-reactive cyanine,
[129,130] acridine,[131]
and photoreducible N-methylpyridinium.[118] Linkers that dis-
play photoisomerization include azobenzene and coumaric acid.
Their activation occurs most optimally in a specific range of
wavelength as plotted.[22]
3.2.2. Linker Cleavage
Ortho-Nitrobenzene Heterolysis: ONB linkers are most ac-
tively used and broadly defined to include ortho-nitrophenylethyl
(NPE),[132–134] ortho-nitrodibenzofuran (NDBF),[124] and ortho-
nitromandelic acid (NM).[135–137] Their photolysis occurs very ef-
fectively by UV absorption,[23,24,138–142] or less effectively by visi-
ble light absorption via two-photon absorption (710 nm,[124] 750
nm[123,141]). Their mechanism of photolysis involves C─O bond
heterolysis that proceeds through a series of intermediate species
that are charged including aci-nitro as depicted in Figure 3A.[143]
Due to such charge generation, the kinetics of ONB photolysis
is influenced by media pH conditions,[143,144] with faster photol-
ysis occurring under basic or acidic pH conditions than physi-
ological pH 7.4.[21,144,145] This pH dependency can be beneficial
for the drug release in tumor environments where extracellular
matrices are maintained slightly acidic (pH 6.2–6.9)[11,146] and in
subcellular endosomes (pH 5.0–6.0)[47] where NPs are taken up
and temporarily retained.
TNB follows a similar mechanism of photolysis like ONB by
forming an aci-nitro intermediate (Figure 3B).[126,138] It occurs
by absorption at long wavelength UV (365 nm) with high quan-
tum efficiency (Φ = 0.19–0.2)[126] comparable to ONB (Φ = 0.01–
0.7).[22] However, use of TNB linkers offers practical advantages
that include synthetic convenience and a structural symmetry by
which two identical arms, each terminated with alcohol or car-
boxylic acid, are amenable for both drug and NP conjugation as
illustrated.
Linker Homolysis: A group of linkers undergo homolytic
bond dissociation for their photolysis as shown by those de-
rived from coumarin (𝜆max = 420 nm),[122,125,127,128] quinoline
(458 nm),[148–151] and carbazole.[152,153] This is illustrated with a
linker such as coumarin-4-methyl[127] that shows cleavage at its
C4 position where its payload is attached (Figure 3C).[141] Its pho-
tolysis occurs effectively by UV–vis absorption (365 nm,[127,154]
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Figure 3. Characteristic mechanisms of linker photolysis. A) ortho-nitrobenzene (ONB) heterolysis, B) Thioacetal ortho-nitrobenzene (TNB) heterolysis,
C) Coumarin bond homolysis.[22,147]
475 nm[155]) or by two-photon NIR absorption (740 nm,[127,154]
800 nm[155]).[127] The kinetics of coumarin photolysis is pH-
dependent like ONB linkers, which occurs faster under an acidic
or basic environment than at pH 7.4.[21,138,156,157] This is at-
tributable to its pH-variable absorptivity (𝜖) and charges gener-
ated in the linker and its payload after their dissociation.
Linker Oxidation and Reduction: Linker cleavage is induced
indirectly through linker oxidation by reaction with 1O2 pro-
duced under the irradiation condition,[114,115,129,130,158] or reduc-
tion via photoelectron transfer.[118] This occurs in a cyanine
class of linker, which shows an oxidative fragmentation by
Vis–NIR irradiation (690 nm, 780 nm) as illustrated in Fig-
ure 4A.[129,130,158] Of interest is its dual function by serving as
PS itself that catalyzes 1O2 production,
[129,130] and then partici-
pating in [2+2] cycloaddition with 1O2 that results in its diox-
etane adducts. Due to their instability, these adducts rapidly
undergo a series of self-fragmentations and cellular hydroly-
sis, leading to its payload release. Linker cleavage via oxida-
tive fragmentation also occurs in other linker types that in-
clude alkene,[114] bis(alkylthio)ethene,[115,159] alkylsulfide,[116] and
bis(alkoxy)anthracene[32,117] (Figure 4B). Each cleavage is trig-
gered by 1O2 reaction, but it varies in its fragmentation pattern.
In addition to oxidation, photoreduction is applicable for linker
cleavage but in fewer linkers such asN-methylpyridinyl-4-methyl
that occurs via photoelectron transfer (Figure 4C)[118] and fluo-
rophore boron-dipyrromethene (BODIPY) (Figure 4D).[119]
3.2.3. Photoisomerization
Despite lack of linker cleavage, photoisomerization enables a re-
lease mechanism by serving as an on–off switch in response to a
light stimulus.[120,160–162] This occurs in double bond-based link-
ers such as azobenzene, coumarate, and fumarate that have abil-
ity for isomerization between two conformational states, trans
and cis, each displaying a distinct molecular shape (Figure 5).
Its on–off function is based on directing their isomerization at
either trans or cis conformation, which is achieved by irradiation
at a specific wavelength. This is illustrated by azobenzene that ex-
ists as a trans-azo form under a visible condition but isomerizes
to a cis-azo form when the light is switched to shorter UV. Use
of this isomerization strategy has proven highly effective in the
design of gating or disassembly systems.[120,160–165]
4. Therapeutic Release via Linker Photolysis
4.1. Cytotoxic Agents
4.1.1. Methotrexate (MTX)
MTX is a cytotoxic drug that inhibits dihydrofolate reductase
localized in cytosol.[166] Despite its antitumor activity, MTX
shows lack of tumor selectivity and dose-limiting toxicity.[167]
Its photocontrolled delivery was achieved by MTX conjuga-
tion through an ONB linker to a folate receptor (FAR)-targeted
poly(amidoamine) (PAMAM) dendrimer.[24,138] Exposure of this
conjugate to medium or long wavelength UV led to rapid MTX
release via ONB photolysis.[24,138] The drug release was verified
independently in a cell viability assay performed using FAR(+)
KB tumor cells that showed light-dependent induction of potent
cytotoxicity.[24]
4.1.2. Doxorubicin (DOX)
DOX (adriamycin) is an anticancer agent that blocks DNA repli-
cation by inhibiting topoisomerase II.[168] Like most cytotoxic
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Figure 4. Mechanisms of photooxidation and photoreduction applied in linker cleavage. A) Oxidative fragmentation of a cyanine linker by [2+2] 1O2
addition. Reproduced with permission.[129] Copyright 2014, American Chemical Society. B) Oxidative fragmentation of vinyl diether by [2+2] 1O2 ad-
dition. Reproduced with permission.[114] Copyright 2012, Royal Society of Chemistry. C) Reductive cleavage of N-methylpyridinyl-4-methyl via electron
transfer. Reproduced with permission.[118] Copyright 2011, Royal Society of Chemistry. D) Reductive cleavage of 4-hydroxybenzyl coordinated to BODIPY.
Reproduced with permission.[119] Copyright 2015, Royal Society of Chemistry.
agents, DOX lacks tumor specificity, and it has been frequently
applied in drug delivery systems based on dendrimer,[23,142,169]
brushed polymer,[170] and UCN.[142,171] One such system involves
folate (FA)-conjugated PAMAM dendrimer employed for tumor-
targeted DOX delivery (Figure 6A).[23] DOX was loaded in this
dendrimer by its covalent attachment through ONB. Irradiation
of the ONB caged DOX[142] or its dendrimer conjugate[23] at
365 nm resulted in rapid DOX release. This was consistent with
induction of potent cytotoxicity in FAR(+) KB cells by irradia-
tion in vitro. In a follow-up study, Wong et al. studied photolytic
DOX release using TNB-cagedDOX,whichwas conjugated to the
FA-conjugated PAMAM dendrimer.[169] This conjugate showed
light-controlled DOX release, which was similarly verified by the
induction of cytotoxicity observed in FAR(+) KB cells. In each of
these systems, DOX delivery using the FA-conjugated dendrimer
resulted in an FAR-specific cellular uptake and greater cytotoxic-
ity than its nontargeted comparator. This points to an important
role of tumor targeting in addition to the precise control of drug
release.108
Linker photolysis for DOX release is achievable by NIR irra-
diation using UV-emitting UCNs.[142,169,171] Wong et al. reported
such a release system designed with mesoporous silica oxide
(mSiO2)-coated UCN (UCN@mSiO2) (Figure 7A).
[142] Its silica
surface was functionalized with FA-conjugated dendrimer for
FAR targeting and conjugated with ONB-cagedDOX. Its DOX re-
lease was demonstrated to occur by irradiation at not only 365 nm
but also 980 nm. They verified the effectiveness of tumor-targeted
DOX delivery in FAR(+) KB cells in vitro, in which cell death
occurred selectively only with the cells treated with the drug-
loaded UCN and exposed to NIR at 980 nm. In a continued study,
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Figure 5. Release systems controlled by photoisomerization via pore gating (upper, middle) or host–guest decomplexation (lower).[120,160–162]
Wong et al. applied this UCN nanocomposite for DOX delivery
by NIR-controlled TNB photolysis.[169] TNB-caged DOX was at-
tached to the outer surface of UCN coated with a mesoporous
silica layer.[98,169] As anticipated, this drug-loaded nanocomposite
showed an FAR-specific uptake as well as induction of cytotoxic-
ity in FAR(+) KB cells in response to irradiation at 980 nm. Other
approaches have been also effectively demonstrated for the NIR
release of DOX loaded in UCNs. Dcona et al. reported a noncova-
lent approach based on the electrostatic adhesion of ONB-caged
DOX on the UCN surface.[171] Xiang et al. coated a layer of ONB-
caged polymer on the UCN surface prior to encapsulation with
unmodified DOX.[173] Irradiation at 980 nm led to polymer frag-
mentation via ONB photolysis, ensuing DOX release.
4.1.3. 5-Fluorouracil (5-FU)
As an inhibitor of thymidylate synthase, 5-FU has been actively
employed in a number of delivery systems. In a first report, Agasti
et al. designed AuNP conjugated with 5-FU through an ONB
linker,[140] and demonstrated a precise control of its drug release
by long wavelength UV (Figure 6B). The drug release was con-
sistent with the induction of cytotoxicity in cancer cells in vitro.
Another system for 5-FU delivery was designed by Liu et al. us-
ing semiconductor QD by its tethering through an N-methyl-4-
picolinium linker.[118] Unlike ONB, this linker cleavage occurs re-
ductively via photoinduced electron transfer from the QD core to
the drug-attached picolinium group. Such QD-mediated photol-
ysis occurs by irradiation in a visible region in which most QDs
show strong absorption. Another approach for photolytic 5-FU
release involves a retro [2+2] dissociation reaction as reported by
Jin et al.[176] For this purpose, they prepared polymer micelles
by self-assembly of coumarin ester-appended poly(methacrylate)
copolymer. The coumarin ester enabled for drug conjugation via
its [2+2] cycloaddition with 5-FU. Micelle photolysis at 254 nm
led to 5-FU release, which occurred through linker photolysis via
retro [2+2] reaction.
4.1.4. Taxane
Despite numerous reports on photocaged taxane
derivatives,[177–180] their application in delivery systems has
been rarely studied. Xu et al. reported such a delivery system
for paclitaxel using a pyramid-shaped RNA nanocage.[181] The
drug was attached through ONB at the end of an RNA branch
extended from the main nanocage.[181] Paclitaxel release oc-
curred by UV irradiation, and it was verified by the induction of
cytotoxicity in breast cancer cells in vitro.
4.1.5. Camptothecin
This anticancer agent blocks DNA replication by inhibiting topoi-
somerase I. Hu et al. reported a polymermicelle system designed
for camptothecin delivery. Its micellar surface was functional-
ized with FA for tumor targeting,[182] while its hydrophobic core
was encapsulated with ONB-caged camptothecin.[182] This mi-
celle showed an FAR-specific uptake in cancer cells, and it re-
leased camptothecin via ONB photolysis that resulted in∼10-fold
greater cytotoxicity than no irradiation in vitro.
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Figure 6. Therapeutic release via linker photolysis at long wavelength UVA. A) Structure of FA-conjugated generation 5 (G5) PAMAM dendrimer which
is attached with ONB-caged DOX, G5(FA)(DOX) (left), and its induction of cytotoxicity in FAR(+) KB cells by irradiation at 365 nm (right). Reproduced
with permission.[23] Copyright 2010, Royal Society of Chemistry. B) AuNP attached with 5-FU on the surface, AuNP@5-FU, for its photochemical delivery
to cell. Reproduced with permission.[140] Copyright 2009, American Chemical Society. C) Polymyxin B-conjugated dendrimer attached with ONB-caged
ciprofloxacin, G5(PMB)(Cipro), for light-controlled ciprofloxacin release in bacterial cells. Reproduced with permission.[172] Copyright 2010, Royal Society
of Chemistry.
4.1.6. Chlorambucil
It is one of alkylation agents that display potent anticancer activi-
ties. Yu et al. reported pyrene-caged chlorambucil loaded in poly-
mer NPs prepared by its aggregation with mPEG-block-poly(L-
lysine).[183] The drug release was demonstrated by irradiation at
365 nm in a cell-based assay, which led to cancer cell death in
vitro. Photolytic chlorambucil release is achievable using a vis-
ible light-responsive linker as reported by Janett et al.[131] They
designed prodrug aggregates made of chlorambucil caged with
acridin-9-methanol, which showed the drug release by irradia-
tion at 410 nm. Linker photolysis at other visible wavelengths
was achieved using a pair of donor and acceptor dye molecules
which served as a UV-emitting transducer. Huang et al. pre-
pared a BODIPY dye-encapsulated mesoporous silica nanocap-
sule, which was then loaded with coumarin-caged chlorambucil
in its shell layer.[184] Linker photolysis occurred by irradiation at
650 nm, which resulted in luminescence emission at 432 nm by
the BODIPY dye pair. Its drug release was confirmed by tumor
cell death observed in vitro. Furthermore, long wavelength pho-
tolysis was achieved at NIR using lithium niobate (LiNbO3), a
photoactive NP that displays two-photon absorption at 790 nm
with luminescence emission at UV–vis bands.[111] Its surface
was conjugated with coumarin-caged chlorambucil, and its drug
release occurred by irradiation at 790 nm via coumarin linker
photolysis.
4.1.7. Platinum-Based Agents
Linker photolysis is applicable in the release of a platinum an-
ticancer agent using its oxidized prodrug, which is released via
photoinduced reduction.[185] Li et al. designed human serum
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Figure 7. Photolytic release systems based on NIR-responsive upconversion nanocrystal (UCN). A) Left: Transmission electron microscope image of
UCN (NaYF4:25%Yb/0.3% Tm) (upper) and its upconversion luminescence spectrum acquired by continuous wave laser excitation at 980 nm (lower).
Right: A modular assembly of UCN by covalent conjugation of G5(FA) dendrimer and ONB-caged DOX on its surface. Reproduced with permission.[142]
Copyright 2015, The Wiley & Sons. B) A schematic illustration for a multifunctional UCN nanocomposite (NaYF4:Yb/Tm) loaded with a platinum(IV)
prodrug for NIR-controlled imaging and antitumor therapy in vivo. Reproduced with permission.[174] Copyright 2013, American Chemical Society. C)
NIR light-triggered sulfur dioxide (SO2) generation using SO2 prodrug-loaded rattle-structured upconversion@silica nanoparticles. Reproduced with
permission.[175] Copyright 2019, American Chemical Society.
albumin carrying a Pt(IV) prodrug linked through amide conju-
gation. Its irradiation enabled to release a reduced, active Pt(II)
species, which was verified by the induction of potent cytotoxicity
in cisplatin sensitive as well as resistant cancer cells. Reductive Pt
release was also achieved using polymer micelles as reported by
Song et al.[186,187] They designed an azide or pyridine-coordinated
Pt(IV) prodrug, which was then encapsulated in the hydropho-
bic core. Irradiation resulted in the prodrug activation to Pt(II),
which rapidly escaped from the hydrophobic core. Using a UCN
nanocarrier opens a route for the NIR-activated Pt(II) release.
Dai et al. designed a UCN nanocomposite loaded with an azide-
coordinated Pt(IV) prodrug on its shell surface (Figure 7B).[174]
Irradiation at 980 nm enabled Pt(II) release, which was consis-
tent with the inhibition of tumor growth in mice treated with the
composite.
4.2. Antibacterial Agent
Ciprofloxacin displays its potent antibacterial activities by in-
hibiting a bacterial DNA gyrase.[188] Shi et al. reported a PEG-
based hydrogel loaded with ciprofloxacin by attachment through
an ONB linkage.[189] Irradiation at 365 nm resulted in the drug
release as verified by the induction of its potent antimicro-
bial activity against Staphylococcus aureus. Its controlled deliv-
ery is achievable using a bacteria-targeted system as reported
by Wong et al. using PAMAM dendrimer functionalized with
PMB, a bacteria-targeting ligand validated for selective binding to
lipopolysaccharide present in Gram(−) bacterial cells.[172,190] Irra-
diation of this targeted dendrimer coconjugated with ONB-caged
ciprofloxacin resulted in the rapid release of ciprofloxacin (Fig-
ure 6C).[172] This was also confirmed in a bacterial growth assay,
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indicating a potent antimicrobial activity induced under the light
condition only.
4.3. Nucleotides
Linker photolysis is also applicable for large biomacromolecules.
Han et al. applied this approach for DNA delivery using AuNP as
a nonviral vector.[191] They fabricated AuNP by surface coating
with positively charged, ONB-caged PEG chains prior to load-
ing of dsDNA (37-mer) on this functionalized AuNP via poly-
plex formation. By irradiation at 350 nm, its PEG surface showed
charge neutralization due to ONB detachment, which promoted
its dsDNA release through surface charge repulsion. Brown et al.
reported a similar approach using AgNP covered with an anti-
sense DNA oligonucleotide which was caged with ONB.[192] This
DNA-coated AgNP vector showed photoactivated antisense DNA
release, which was verified in a cellular assay by its ability to
block the expression of its target gene, intracellular adhesion
molecule-1.
Photolysis for nucleotide release is designed using NIR-
responsiveUCN. Pan et al. applied this approach inCRISPR gene
editing for cancer therapeutics.[193] They coated the UCN surface
with ONB-caged Cas9-sgRNA, a single guide RNA that targets
a tumor gene (polo-like kinase-1). NIR irradiation led to desired
gene editing as verified by inhibition of tumor growth in vivo.[193]
Another example for gene release involved UCN loaded with
an ONB-caged morpholino oligonucleotide on the surface.[194]
This system enabled NIR-triggered gene escape in endosomes by
which gene knockdown occurredmore effectively in amelanoma
model.
4.4. Gas Molecules of Biological Significance
Application of controlled release for small di or triatomic gas
molecules is highly challenging due to their lack of functional
moiety for temporary inactivation. It requires other strategies
such as using its donor or precursor molecules as demon-
strated by nitrogen oxide (NO), which has been most actively
studied for light controlled release. Fraix et al. identified a
nitroaniline-based NO donor with ability for NO release via its
photofragmentation.[195] It was loaded in 𝛽-CD-based polymer
NPs through its host–guest complexation in the 𝛽-CD hydropho-
bic cavity along with zinc-phthalocyanine (ZnPc) coloaded as PS.
Irradiation at 400 nm resulted in NO and 1O2 release, both of
which contributed to cell death in melanoma cells in vitro. Appli-
cation of this nitroaniline for NO release was achieved using car-
bon QD as well,[196] in which the NO release is triggered by pho-
toinduced energy transfer from the QD core to the NO donor lo-
calized in the shell. Its release activity was evident with decreased
cell viability in HeLa cells in vitro, and lowered tumor volume in
tumor-grafted mice.
A second approach for NO release relies on using a metal-
NO chelate through photoinduced bond dissociation. Xiang et al.
loaded a ruthenium nitrosyl (Ru-NO) complex on the surface of
FA-conjugated nanoTiO2 for its targeted delivery in FAR(+) HeLa
cells.[197] Visible irradiation above 400 nm resulted in both NO
and 1O2 release by TiO2. This Ru–NO approach was also demon-
strated using graphene QD by its covalent functionalization on
the surface.[198] Irradiation at 808 nm resulted in NO release
along with hyperthermia induction by the QD. This dual therapy
accounted for a potent antitumor efficacy in a tumor model.
Photolytic gas release is broadly applicable to various gas
molecules that include carbon monoxide (CO),[199] sulfur diox-
ide (SO2),
[175] and hydrogen sulfide (H2S).
[200,201] CO release is
achieved using a manganese carbonyl complex with ability to
undergo Mn–CO dissociation by irradiation at 365 nm.[199] This
Mn–CO complex was used for NIR-responsive CO delivery by its
loading in polymer-coated UCN as reported by Pierri et al.[199]
Such NIR approach was also applied for SO2 delivery using
UCN@mSiO2 loaded with thiophene-1,1-dioxide as the SO2 pre-
cursor (Figure 7C).[175] H2S release is achieved in a prodrug ap-
proach such as using an ONB-caged precursor.[200] Chen et al.
designed PEG-coated UCN for encapsulation of this ONB-caged
H2S precursor in its shell layer,
[200] and showed H2S release by
excitation at 980 nm.
In section summary, linker photolysis constitutes a signifi-
cant fraction of research efforts in the development of photoac-
tivated release systems. As summarized in Table 1, its applica-
tions are validated in a wide range of therapeutic molecules from
antitumor agents[11,13,103,202] (DOX,[23,203] 5-FU,[140] MTX,[24,138]
paclitaxel,[126,177] camptothecin[182]), antibacterial agents,[172] gas
molecules (NO,[195,197] CO,[199] H2S
[201]) to nucleotides.[193]
5. Therapeutic Release via Photolytic Disassembly
5.1. Liposome Disassembly
Photolytic disassembly is defined arbitrarily as a process in which
drug molecules loaded in a nanocontainer are released upon its
nanocontainer disassembly triggered by photolysis. This is ap-
plicable in a liposomal structure made of photocleavable lipids
within its bilayer structure. Chandra et al. reported anONB-caged
liposome that showed disassembly by irradiation at 365 nm.
It was successfully used to release 6-carboxyfluorescein loaded
internally.[204] This liposomal control was similarly applied in the
release of a magnetic resonance imaging (MRI) contrast agent
using an ONB-caged Gd(III) complex which was tethered to
the water-exposed surface.[205] Its release resulted in a decrease
in T1 relaxivity when the liposome was photolyzed at 400 nm.
5.2. Polymer Micelle Disassembly
5.2.1. Disassembly via UV–Vis Photolysis
Polymer micelle disassembly has proven effective in the
controlled release of payloads such as dye[119,206] and drug
molecules.[207,208] It is illustrated with the release of Nile red
encapsulated in polymer micelles (polymersomes) made of ei-
ther ONB-caged block copolymer,[206] or photocleavable BODIPY
polymer.[119] These micelles showed degradation upon irradia-
tion at 365 nm (ONB) or 470–490 nm (BODIPY), which was
attributed to photolytic degradations at the hydrophobic core.
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Table 1. Therapeutic release via linker photolysis.
Therapeutic area Nano delivery system Design Refs.
Payload Linker (Light, nm)
Anticancer G5(FA)(MTX) MTX ONB (365) [24,138]
G5(FA)(DOX) DOX ONB (365 ), TNB (365) [23,169]
UCN@G5(FA)-DOX DOX TNB (980) [142]
UCN@DOX DOX ONB (980) [171]
AuNP@5-FU 5-FU ONB (365) [140]
QD@5-FU 5-FU N-Methyl-4-picolinium (Vis) [118]
Poly(methacrylate) micelle 5-FU [2+2] Addition (254) [176]
RNA nanocage Paclitaxel ONB [181]
Polymer micelle Camptothecin ONB [182]
Poly(l-lysine) Chlorambucil Pyrene (365) [183]
NP aggregate Chlorambucil Acridin-9-methanol (410) [131]
Mesoporous silica nanocapsule Chlorambucil Coumarin (650) [184]
LiNbO3 Chlorambucil Coumarin (790)
[111]
Human serum albumin Pt(II) Pt(IV) azide [185]
Polymer micelle Pt(II) Pt(IV) azide [186,187]
UCN@Pt(IV) Pt(II) Pt(IV) (980) [174]
Antibacterial PEG hydrogel Ciprofloxacin ONB (365) [189]
G5(PMB)(Cipro) Ciprofloxacin ONB (365) [172]
Nucleotide AuNP@dsDNA dsDNA ONB (350) [191]
AgNP@DNA Antisense DNA ONB [192]
UCN@RNA Cas9-sgRNA ONB (980) [193]
Gas Molecule 𝛽-CD polymer NO Nitroaniline (400) [195]
QD@nitroaniline NO Nitroaniline (350, 800) [196]
NanoTiO2 NO Ru–NO (400)
[197]
Graphene QD NO Ru–NO (808) [198]
UCN@(Mn-CO) CO Mn–CO (980) [199]
UCN@thiophenedioxide SO2 Thiophenedioxide (980)
[175]
UCN@H2S precursor H2S ONB (980)
[200]
Polymer micelle disassembly is applied in a similar manner for
drug delivery as demonstrated by DOX release from micelles
prepared with ONB-caged amphiphilic block copolymer[208] or
poly(acrylate) ester copolymers.[207]
Micelle disassembly generally occurs regardless of its shape
or surface functionalization. Yang et al. reported DOX-loaded
cylinder-shaped tubisomes made of cyclic peptide-bridged pho-
tocleavable copolymers (Figure 8A).[209] The tubisome disassem-
bly occurred rapidly after irradiation at 365 nm, and DOX release
that followed was consistent with the induction of cytotoxicity in
breast cancer cells. Sun et al. reported CD44-targeted DOX deliv-
ery using polymer micelles made of ONB-caged hyaluronic acid
(HA). This HA polymer was also used to play a role in tumor
targeting[210] because of its affinity to a CD44 biomarker overex-
pressed in cancer cells. DOX release occurred by UV irradiation,
which accounted for potent inhibition of tumor growth in mice.
Tumor-targeted DOX delivery was also achieved using a DNA ap-
tamer Sgc8 conjugated to photocleavable polymer micelles as re-
ported by Yang et al (Figure 8B).[211] They observed selective mi-
celle binding and uptake by leukemia cells, and the induction of
cytotoxicity associated with DOX release by UV irradiation.
Caging with coumarin and other photolabile linker is also ef-
fective in the design of polymer disassembly systems. Sun et al.
designedDOX-encapsulated polymersomes composed of diblock
copolymers caged with coumarin in the shell layer.[213] Irradi-
ation at 430 nm resulted in coumarin detachment, which trig-
gered DOX release via liposome disassembly. Photolytic disas-
sembly was demonstrated using 2-nitroresorcinol polyacetal as
a photolabile polymer as reported by Pasparakis et al.[214] They
prepared polyacetal aggregates encapsulated with camptothecin,
and showed occurrence of polymer disassembly triggered by ir-
radiation with UV or visible light which was less effective.
5.2.2. Disassembly via NIR Photolysis
It is doable to integrate UCN with polymer micelles for NIR-
triggered photolytic disassembly. Yan et al. designed UCN-
encapsulated micelles made of ONB-caged poly(methacrylate)
copolymers (Figure 8C).[212] Irradiation at 980 nm resulted
in micelle disassembly by a mechanism attributed to ONB
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Figure 8. Therapeutic release via polymer disassembly induced by linker photolysis. A) Phototriggered disassembly for drug release by DOX-loaded
tubisomesmade of photocleavable copolymers. Reproduced with permission.[209] Copyright 2020, TheWiley & Sons. B) Aptamer-grafted hyperbranched
polymer micelles for controlled release of Dox by UV irradiation. Reproduced with permission.[211] Copyright 2018, The Wiley & Sons. C) Upconversion
luminescence-controlled disassembly of polymer micelles. Reproduced with permission.[212] Copyright 2011, American Chemical Society.
detachment by UV luminescence emitted from UCN. This ap-
proach allowed to release DOX which was coloaded with UCN
within the micelle.[215] The drug release was consistent with the
induction of cytotoxicity observed in MCF-7 breast cancer cells
under NIR irradiation. This strategy was similarly applied for
NIR-induced siRNA delivery.[216] Here, Zhao et al. designedUCN
coated with ONB-caged cationic brush polymers in order to load
negatively charged siRNA which is encoded to block an intracel-
lular cancer target. By 980 nm irradiation, they were able to re-
lease the siRNA via polymer disassembly that followed ONB de-
tachment. This siRNA delivery proved effective in suppressing
A549 tumor growth in vivo.[216]
5.2.3. Disassembly via Retro [2+2] Reaction
Lastly, design of photolytic disassembly is achievable using retro
[2+2] cycloaddition. Alemayehu et al. designed DOX-loaded poly-
mermicelles prepared by inter-polymer crosslinking via [2+2] cy-
cloaddition of two complementary polymers, each tethered with
adenine (A) or uracil (U).[217] Irradiation at 254 nm led to DOX re-
lease, which was attributed to polymer micelle disassembly that
occurred through polymer de-crosslinking by retro [2+2] reac-
tion. The drug release was confirmed by the induction of cyto-
toxicity in cancer cells.
In summary, linker photolysis has played a growing role in
the control of disassembly that enables payload release. It has
shown promising applications for Nile red,[119,206] DOX,[213,217]
camptothecin,[214] an MRI contrast agent,[205] and siRNA[216] us-
ing nanocarriers based on liposomes, polymermicelles andUCN
as summarized in Table 2.
6. Therapeutic Release via Photolytic Gate Control
Linker photolysis plays a notable role in the control of gat-
ing mechanism for controlled drug release. Lai et al. reported
fluorescein-loadedmesoporous silica nanoparticle (MSN) grafted
with ONB-caged poly(N-isopropylacrylamide-co-acrylate) poly-
mer on its porous surface. Under an ambient condition, its pores
remained closed due to its randomly collapsed polymer brushes
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Table 2. Therapeutic release systems via nanocarrier disassembly or gating enabled by linker photolysis.
Release mode Nano delivery system Design Refs.
Payload Linker (Light, nm)
Disassembly Polymer micelle DOX ONB [207,208]
HA polymer micelle DOX ONB [210]
Polymer micelle-aptamer Sgc8 DOX ONB [211]
Polymer tubisome DOX ONB (365) [209]
UCN@polymer micelle DOX ONB (980) [212,215]
Crosslinked polymer micelle DOX [2+2] Addition (254) [217]
Polymer micelle DOX Coumarin (430) [213]
NP aggregate Camptothecin 2-Nitroresorcinol (UV–vis) [214]
UCN@siRNA siRNA ONB (980) [216]
Liposome Gd(II) complex ONB (400) [205]
Liposome Carboxyfluorescein ONB (365) [204]
Polymer micelle Nile red ONB (365), BODIPY (470) [119,206]
Gating mSiO2@Polymer – ONB
[218]
AuNS@mSiO2 DOX ONB (980)
[219]
UCN@mSiO2 Fluorescein ONB (980)
[220]
mSiO2 Rhodamine Ru–S (455)
[221]
UCN@mSiO2 DOX Ru–S (977)
[222]
(Figure 9A).[218] However, under UV irradiation, they observed
pore opening that allowed payload diffusion. This was attributed
to the loss of ONB moieties, which made polymer brushes more
water soluble and elongated to a preferred conformation for pore
opening.
Hernández-Montoto et al. advanced this gating strategy for
NIR control.[219] They designed mSiO2-coated gold nanostar
(AuNS@mSiO2), which was then loaded with DOX prior to
capping with a layer of photocleavable PEG derivatives on its
silica shell (Figure 9B).[219] Irradiation at 808 nm resulted in
DOX release and the induction of toxicity in HeLa cells, which
was attributed to pore opening associated with polymer photol-
ysis. NIR-controlled photolytic gating was also achieved using
UCN@mSiO2 capped with photocleavable polymers as reported
by Xiang et al.[220] They showed this UCN system for fluorescein
release by NIR irradiation.
Another approach for a gate control in MSN involves an inter-
nal capping within its pore interior in lieu of on its surface. This
was achieved using MSN functionalized internally with thiol-
coordinated ruthenium-bipyridyl moieties (Figure 9C).[221] Visi-
ble irradiation at 455 nm of this MSN loaded with rhodamine
enabled the dye release. This was attributed to its pore opening
which occurred when its ruthenium capping complex dissociated
by Ru-S photolysis. He et al. further advanced this gating strat-
egy for NIR control using mesoporous silica coated UCN that
displayed blue luminescence at 470 nm (Figure 9D).[222] They
demonstrated DOX release by irradiation at 974 nm.
In summary, linker photolysis has been applied for a gate
control using MSN,[218,219] UCN,[222] and their core–shell inte-
gration (Table 2). Despite only a few applications, it shows a
promising potential in the design of gating systems for drug
delivery.
7. Therapeutic Release via Photoisomerization
7.1. Gating via Photoisomerization
7.1.1. Azobenzene/Cyclodextrin Rotaxane
Azobenzene plays an active role in the control of gating by serving
as a photoresponsive switch.[162,223] Zhao et al. reported polymer
vesicles designed to release entrapped drug molecules using this
mechanism (Figure 10A).[163] They designed bacteria-like, rod-
shaped vesicles, which were prepared by the self-assembly of a
host–guest polymer complex referred to as “rotaxane” made be-
tween 𝛽-cyclodextrin (𝛽-CD) and an azobenzene derivative. UV
irradiation of these vesicles entrapped with DOX led to the drug
release by a gating mechanism. This release was attributed to
cilia-like stretchingmotions that occurred in response to azoben-
zene decomplexation from its rotaxane when it isomerized to cis
conformation.
Designing a gating mechanism using an azobenzene/CD
rotaxane is also applicable in MSN, which contains inter-
nal pores.[160,224] Yan et al. generated gate keepers at its sur-
face by capping with azobenzene/𝛼-CD rotaxane shuttles (Fig-
ure 10B).[160] Such design made its pores either closed under
UV light (cis, rotaxane decomplexed) or open under visible light
(trans, rotaxane complexed). Using this delivery system, they suc-
cessfully demonstrated curcumin release in zebrafish larvae un-
der visible light irradiation. Wang and Wu reported a MSN sys-
tem similarly functionalized with azobenzene/𝛽-CD complexes,
which was effectively used for DOX release in porcine skin
under red light (625 nm).[224] Lastly, Yuan et al. reported an-
other type of gating mechanism for MSN by functionalization
with a DNA strand hybridized with an azobenzene-containing
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Figure 9. Photolytic gate control designed with mesoporous silica nanoparticles (MSN). A) MSN coated with polymer brushes. Reproduced with
permission.[218] Copyright 2010, Royal Society of Chemistry. B) DOX-loaded AuNS@mSiO2 nanoparticles capped with a photolabile PEG derivative.
Reproduced with permission.[219] Copyright 2019, Royal Society of Chemistry. C) MSN encapsulated with Dye Sr101 and functionalized with thiol-
coordinated Ru(bpy)2(PPh3) moieties inside the pores. Reproduced with permission.
[221] Copyright 2011, Royal Society of Chemistry. D) DOX-loaded
UCN@mSiO2 nanoparticles capped with a photocleavable Ru complex. Reproduced with permission.
[222] Copyright 2015, Royal Society of Chemistry.
complementary DNA strand (Figure 10C).[164] This particular de-
sign allowed a pore closing at DNA hybridization (trans, visible)
due to steric blocking by dsDNA, which switched to an opening at
dsDNA dehybridization (cis, UV). This delivery system was suc-
cessfully demonstrated for DOX release following irradiation at
365 nm.
NIR-controlled isomerization is applicable in the design of gat-
ing mechanisms. Liu et al. reported DOX-loaded UCN@mSiO2
which was then modified by capping with azobenzene residues
at its pores (Figure 11A).[161] Its irradiation at 980 nm resulted in
DOX release, which was attributed to pore opening by trans to cis
isomerization at the pore entrance. This UCN-enabled NIR con-
trol was successfully applied in another delivery vehicle such as
UCN-encapsulated azobenzene vesicles as reported by Yao et al.
(Figure 11B). Irradiation at 980 nm of the vesicles coloaded with
DOX resulted in effective drug release.[120]
7.1.2. Emerging Host–Guest Systems
In addition to CD, there are various types of host molecules that
are effectively applied in gating systems. These include cucur-
bit[8]uril, a pumpkin-shaped hollow container, that is also able
to form a rotaxane complex. Ma et al. reported MSN functional-
ized with trans-azobenzene peptide derivatives, each engaged in
forming a rotaxane shuttle with cucurbit[8]uril.[225] Irradiation at
350 nm of this MSN loaded with DOX enabled DOX release due
to its pore opening that occurred in response to rotaxane decom-
plexation.
Gate controls are also achieved using other photoisomer-
ization systems based on coumarate,[226] fumaramide,[165]
spiropyran,[227] and a donor–acceptor Stenhouse adduct
(DASA).[228] Like azobenzene, coumaric acid attached on
the MSN surface allowed light-controlled release of naproxen,
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Figure 10. Gating control by photoisomerization. A) Light-triggered gate opening for DOX release in bacteria-like vesicles. Reproduced with
permission.[163] Copyright 2014, American Chemical Society. B) Visible light-triggered gate opening for curcumin release in zebrafish larvae. Repro-
duced with permission.[160] Copyright 2012, The Wiley & Sons. C) Gating control via dsDNA dehybridization triggered by azobenzene isomerization.
Reproduced with permission.[164] Copyright 2012, American Chemical Society. D) Isomerization-induced control of rotaxane (fumaramide-CD complex)
shuttling between a proximal (closed) and distal (open) position. Reproduced with permission.[165] Copyright 2015, Royal Society of Chemistry.
a nonsteroidal anti-inflammatory drug, loaded in silica pores
following irradiation at 254 nm.[226] Fumaramide plays a sim-
ilar role as applied in the design of its rotaxane-guided gating
system. Martinez-Cuezva et al. designed MSN attached with
a fumaramide-containing peptide in complex with [2]rotaxane
(Figure 10D).[165] This design allowed its pore opening at 365 nm
(trans) by which its payload rhodamine B was released. Spiropy-
ran engages in a gate control though it works differently by
displaying different properties upon isomerization between its
cyclic hydrophobic form at >450 nm and its open zwitterionic
form at <420 nm. Wang et al. used such distinct property in
the gate control of polymer vesicles made of a spiropyran-
branched copolymer.[227] These vesicles remained tightly sealed
at >450 nm, but developed porosity after irradiation at <420 nm,
which was attributed to an increase in internal hydrophilicity
due to isomerization to zwitterions. Lastly, a functional unit
known as a donor-acceptor Stenhouse adduct (DASA)[228] offers
an unique ability to undergo an intramolecular cycloaddition
at 550 nm by which its physicochemical property is reversed
from hydrophobicity to hydrophilicity. Such physicochemical
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Figure 11. NIR-controlled gating systems designed with upconversion nanocrystal (UCN). A) NIR-triggered release of DOX loaded in UCN@mSiO2
grafted with azobenzene molecules in its mesoporous network by trans to cis photoisomerization. Reproduced with permission.[161] Copyright 2013,
The Wiley & Sons. B) A schematic illustration for azobenzene-incorporated vesicles encapsulated with DOX and UCN for NIR-controlled drug release.
Reproduced with permission.[120] Copyright 2016, The Wiley & Sons.
alterationwas used to control the release of DOXor camptothecin
loaded in DASA polymer NPs designed for FAR-targeted drug
delivery.[228]
7.2. Disassembly via Photoisomerization
7.2.1. Azobenzene Micelle
Azobenzene photoisomerization constitutes a prominent princi-
ple in the function of disassembly systems. One such system in-
volves liposomes assembled with azobenzene lipid molecules as
reported by Liang et al.[229] They demonstrated its ability to en-
gage in an on–off switch by light such that the liposome remained
intact under visible light at 450 nm, but disassembled after irradi-
ation at 365 nm.Namazi and Jafarirad effectively applied this con-
cept for the light controlled release of erlotinib, which was encap-
sulated in polymer micelles prepared with azobenzene-grafted
dendrimer copolymer.[230]
Azobenzene isomerization is equally applied in azoben-
zene/CD complexes for disassembly control. Yan et al. demon-
strated the disassembly of tube-shaped vesicles made of azoben-
zene poly(acrylate) and 𝛼-CD poly(caprolactone)[231] which oc-
curred following irradiation at 365 nm (Figure 12A). They fur-
ther applied this strategy for the controlled release of propranolol
(𝛼-blocker) encapsulated in the same vesicles.[234] Azobenzene
isomerization normally occurs by absorption in a UV or visible
range, though it can also occur in a longer NIR region via energy
transfer. Huang et al. reported such polymer micelle disassem-
bly for DOX release in HeLa cells that occurred by two-photon
absorption of the azobenzene polymer at 800 nm through its flu-
orescence resonance energy transfer.[235]
Besides small drug molecules, release by disassembly is appli-
cable for larger siRNA. Li et al. designed positively charged NPs
made of azobenzene/CD-HA complexes,[236] which was used for
loading siRNA (GAPDH-homo). This siRNA release occurred
through vesicle disassembly following irradiation at 365 nm,
which was consistent with the induction of growth inhibition in
cancer cells. In other similar applications, release by disassem-
bly occurs as a result of changes in shape. This is illustrated by
azobenzene/CD polymer vesicles which shifted their shape from
soft vesicles to smaller compact NPs after UV irradiation.[237]
7.2.2. Donor–Acceptor Stenhouse Adduct (DASA) Polymer
Triggering polymer disassembly is achievable through the iso-
merization of the DASAmoiety. Poelma et al. reported paclitaxel-
loaded micelles containing DASAmoieties localized in the inner
layer.[238] Following exposure to visible light at 550 nm, these mi-
celles showed disassembly, which was attributed to increased hy-
drophilicity associated with cyclized DASAmoieties. This system
was effectively used for paclitaxel delivery inMCF-7 breast cancer
cells that occurred under visible light irradiation.
7.2.3. Hydrogel
Defined as a polymer network which is crosslinked covalently
or noncovalently, hydrogel retains its shape with the help of
such crosslinks. Peng et al. designed a hydrogel disassembly
system using a noncovalent azobenzene/CD crosslinker as the
photoswitch (Figure 12B).[232] They demonstrated an effective re-
lease of green fluorescent protein (GFP) which was preloaded by
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Figure 12. Release systems of photoisomerization-induced disassembly. A) A schematic for photoresponsive disassembly by nanotubes made of PCL-
𝛼-CD and PAA-Azo. Reproduced with permission.[231] Copyright 2011, Royal Society of Chemistry. B) Release of green fluorescent protein (GFP) from
an azobenzene/𝛽-CD hydrogel by UV isomerization. Reproduced with permission.[232] Copyright 2010, Royal Society of Chemistry. C) DOX release by
NIR-induced disassembly of hollow nanocapsule@up/downconversion NP. Reproduced with permission.[233] Copyright 2018, The Wiley & Sons.
irradiation at 365 nm. Karcher and Pianowski similarly applied
this release strategy for ciprofloxacin which was encapsulated in
an azobenzene-based photochromic hydrogel.[239] Its release oc-
curred precisely when the hydrogel (trans) turned to a liquid form
(cis) under green light (510 nm). This was consistent with the
inhibition of Escherichia coli growth under 523 nm light, which
was in contrast with its normal growth observed under the dark
condition.[239]
7.2.4. Metal-Organic Framework
Using an azobenzene switch is effectively applied in the control
of physical stability in metal-organic framework (MOF). This is
illustratedwith azobenzenedicarboxylate whichwas incorporated
within the lattice of UiO-type MOF as an organic ligand.[240] This
MOF remained stable in the dark but showed degradation after
irradiation at 340 nm. This disassembly strategy was effective in
the controlled release of 5-FU loaded in the MOF.
7.2.5. Core–Shell UCN
Integration of UV–vis luminescent UCN and azobenzene sys-
tems offers a principal route forNIR-controlled disassembly. This
is illustrated with azobenzene/CD-coated UCN, which displayed
polymer disassembly at 980 nm as reported by Möller et al.[241]
Zhao et al. directed this strategy to drug delivery by designing
DOX-loaded nanocapsule, in which DOX was coencapsulated
with UCN in its shell layer made of azobenzene polymers (Fig-
ure 12C).[233] Irradiation at 980 nm resulted in DOX release,
which was verified with the induction of potent cytotoxicity in
tumor cells.
In section summary, photoisomerization actively engages in
the design of release systems controlled via either gating or disas-
sembly. This strategy has been widely applied as evident with nu-
merous delivery systems based on MSN, micelles, polymer mi-
celles, hydrogel, MOF and UCN, and various types of payloads
including DOX, paclitaxel, 5-FU, ciprofloxacin or GFP (Table 3).
8. Therapeutic Release by Photothermal Activation
8.1. Photothermal Gating
Yagüe et al. explored this gating mechanism using ibuprofen-
loaded MSN, which was coated with a porous layer of Au on
its shell surface.[242] Its ibuprofen release occurred by NIR ex-
posure at 808 nm, which was attributed to pore opening induced
by heat production in Au. Marquez and Scaiano advanced this
strategy for naproxen delivery using a mesoporous nanomaterial
coloaded with AuNR. Its pores were sterically blocked by capping
with a cucurbit[6]uril derivative via host–guest complexation.[243]
Its drug release occurred in responsive to green light or NIR ir-
radiation, which was absorbed for heat production by AuNR. An-
other example for photothermal gating involved isomerization-
controlled rotaxane shuttling at the pore entrance. Li et al. re-
ported mesoporous silica-coated AuNR, which was loaded with
DOX prior to capping with cis-azobenzene/𝛽-CD rotaxane in its
shell layer.[244] This design allowed DOX release under visible ir-
radiation at 543 nm, which was attributed to thermally-induced
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Table 3. Therapeutic release via photoisomerization-induced gating and disassembly.
Release mode Nano delivery system Design Refs.
Payload Linker (Light, nm)
Gating mSiO2@Azo/CD Curcumin Azobenzene/CD (Vis)
[160]
Supramolecular vesicle DOX Azobenezene/CD (UV) [163]
mSiO2@Azo/CD DOX Azobenzene/CD (650)
[224]
mSiO2@Azo-dsDNA DOX Azobenzene (365)
[164]
UCN@Azo DOX Azobenzene (980) [161]
UCN@Azoliposome DOX Azolipid (980) [120]
MSN@Azo/cucurbituril DOX Azobenzene/cucurbituril (350) [225]
MSN@coumarate Naproxen Coumarate (254, 365) [226]
MSN@fumaramide/rotaxane Rhodamine B Fumaramide/rotaxane (365) [165]
Polymer vesicle DAPI Spiropyran (420) [227]
Folate polymer NP DOX, Camptothecin DASA (550) [228]
Disassembly Polymer micelle Nile Red Azobenzene (365) [229]
Polymer micelle Erlotinib Azobenzene (365) [230]
HA polymer NP siRNA Azobenzene/CD (365) [236]
Azo/CD polymer micelle Rhodamine B Azobenzene/CD (365) [231]
Azo/CD polymer micelle (R/S)-Propranolol Azobenzene/CD (UV) [234]
Azo/CD polymer micelle DOX Azobenzene/CD (800) [235]
Polymer micelle Paclitaxel DASA (550) [238]
Hydrogel GFP Azobenzene/CD (365) [232]
Hydrogel Ciprofloxacin Azobenzene (523) [239]
MOF@5-FU 5-FU Azobenzene (340) [240]
UCN@DOX DOX Azobenzene/CD (980) [233]
isomerization to trans-azobenzene due to AuNR photothermal
heating. This delivery condition proved effective for in vivo DOX
delivery in zebrafish embryo. Last, another approach for a gat-
ing control in pore-loaded MSN involves surface coating with a
polymer layer encapsulated with AuNP as demonstrated for rho-
damine B release.[245]
HAuNS,[246] a class of nanogold that shows interior cavity-
tunable surface plasmon activation, has played an important role
in controlled drug release via photothermal gating.[79] Li et al. de-
signed PEG-coated HAuNS, which was then loaded with DOX,
and demonstrated its controlled DOX release by NIR irradia-
tion at 808 nm.[77] This release was consistent with the induc-
tion of photocytotoxicity observed in cell studies using MDA-
MB-231 cells.[77] They further developed this photothermal sys-
tem for the co-delivery of DOX and combretastatin A-4 phos-
phate for treating hepatocellular carcinoma,[75] and expanded
its applications to numerous anticancer therapeutics including
paclitaxel,[247] cisplatin,[83] and siRNA.[84]
AuNC, another distinct class of nanogold, also offers capabil-
ity for photothermal pore gating.[79] Yavuz et al. reported DOX-
loaded AuNC coated with thermosensitive polymer brushes on
the surface by which DOX was sterically confined within its in-
ternal cavity without premature release.[78] Upon NIR irradiation
at 790 nm, its localized heat production caused polymer brush
shrinkage that triggered pore opening for DOX release. This re-
lease control was consistent with its light-controlled induction of
potent cytotoxicity in breast cancer cells in vitro.[79]
Moreover, nanomaterials other than noble element NPs have
shown potential utility for drug delivery via photothermal gat-
ing. These include Bi2Se3 nanosponge
[248] and carbon dots,[249]
which offer desired features including NIR absorbance, efficient
photothermal conversion, or high loading capacity. Lv et al. em-
ployed carbon dots in the release control of mesoporous silica-
coated UCN nanocapsule, which was co-loaded with DOX and
ZnPc for ROS production.[249] Its payloads retained without dif-
fusion until NIR stimulation at 980 nm when pore opening oc-
curred due to heat generation from the activated carbon dot by
UCN red luminescence. This nanocapsule proved highly effica-
cious in inhibiting tumor growth in vivo, which was attributed
to synergy by a combination of three therapeutic modalities that
comprise of hyperthermia, DOX release, and 1O2.
8.2. Photothermal Disassembly
8.2.1. Liposome Loaded with Photothermal NP
Liposomes constitute one of ideal systems applicable for pho-
tothermal disassembly because theirmembrane rupture is highly
susceptible to a temperature elevation. An et al. designed
berberine-loaded liposomes which contained AuNP embedded
in its lipid bilayer,[250] and demonstrated the drug release in re-
sponse to visible light irradiation. Geng et al. reported using black
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phosphorous QD as a photothermal agent embedded in the lipo-
some membrane.[251] This DOX-loaded liposome proved effec-
tive in killing breast cancer cells by irradiation at 808 nm.
8.2.2. Polymer Micelle Loaded with NIR Dye
NIR absorbing dyes serve as a useful tool in the design of pho-
tothermal disassembly systems. These include cyanine-based
dyes such as cypate[252] and indocyanine green.[253,254] Li et al.
designed cypate-encapsulated polymer micelles which were co-
loaded with a Pt(IV) prodrug.[252] They showed NIR-induced
hyperthermia, which led to its Pt(IV) prodrug release via mi-
celle disassembly. These micelles showed a broad spectrum of
cytotoxicity in various cancer cells including cisplatin resistant
cells. Indocyanine green plays a similar role in the photother-
mal induction of drug release in polymer micelles as applied
for DOX[253] and Pt agent.[254] Their design involved indocyanine
green-encapsulated polymer liposomes coloaded with DOX[253]
or a cisplatin prodrug[254] and under 808 nm irradiation, demon-
strated potent inhibition of tumor cell growth in vitro and in vivo.
Such efficacy was attributed to the dual role of indocyanine dye
in ROS production and localized hyperthermia responsible for
drug release. Besides cyanine dyes, photothermal disassembly
was validated using BODIPY for camptothecin delivery under
NIR irradiation.[255]
8.2.3. Polymer Micelle Loaded with Photothermal NP
Photothermal systems for disassembly have been more ac-
tively studied using nano Au. Takahashi et al. reported AuNR
loaded with plasmid DNA on its surface. They showed its
DNA release by irradiation at 1064 nm.[256] Using AuNR
for photothermal disassembly has further advanced through
its surface functionalization with polymers for drug loading.
This is effectively applied for DOX delivery using a num-
ber of polymers made of PEG-poly(𝜖-caprolactone),[257] poly(N-
isopropylacrylamide),[258] and poly(dopamine) (PDA).[259] They
showed that irradiation at 808 nm induced a phase transition
in the polymer layer, by which DOX was released to kill cancer
cells. Alternatively, AuNR is encapsulated in polymer micelles
as reported by Song et al. in their design of PLGA micelles co-
loaded with reduced graphene oxide (rGO) and DOX.[260] PDA
also serves as an effective agent in inducing photothermal dis-
assembly as applied for DOX delivery by Ding et al.[261] In its
another application, Zhang et al. designed PDA-coated AuNR
loaded with cisplatin in the PDA layer,[259] and further modified
by conjugation with c(RGDyC), a targeting ligand for 𝛼v𝛽3 inte-
grin tumor biomarker. They demonstrated an NIR-induced an-
titumor effect by hyperthermia and cisplatin release in 𝛼v𝛽3(+)
tumors.
Nanogold structured in nonrod shapes are effectively ap-
plied for photothermal disassembly that include Au nanoflower
(AuNF),[266] gold nanosphere,[267] and Au nanoshell (AuNS).[262]
He et al. designed PEG-polystyrene micelle embedded with
AuNF,[266] and showed its photothermal activation at 800 nm
that enabled to release rhodamine B encapsulated in the polymer
layer. Spherical nanogold was also effectively used in the delivery
of siRNA oligonucleotides loaded on the surface of gold-coated
polymer NP as reported by Jeong et al.[267] Irradiation at 808 nm
led to siRNA release in HeLa cells by which its target GFP gene
was effectively silenced. In another shape, Wang et al. reported
AuNS loaded with DNAzyme precursor via complementary hy-
bridization (Figure 13A).[262] Au hyperthermia occurred by irra-
diation at 808 nm, which enabled its payload release via DNA
dehybridization.
8.2.4. Hydrogel Loaded with Photothermal Agent
Use of hydrogel for photothermal disassembly is illustrated with
an indocyanine green dye-encapsulated nanogel, which was co-
encapsulated with DOX.[268] This nanogel showed a phase tran-
sition after NIR irradiation, and its deformation to a sol form
enabled to trigger DOX release and thus induced cytotoxicity in
4T1 cells. Photothermal hydrogels are more actively designed us-
ing noble element NPs made of Au[269] and Pt.[270] These include
an agarose hydrogel loaded with polymer-coated AuNP, which
was demonstrated for the photothermal release of bevacizumab,
a biologic protein, for its potential ocular delivery.[269] Nanoplat-
inum loaded in a hydrogel was also effective for photothermal
activation by NIR irradiation, which resulted in hydrogel degra-
dation and release of bortezomib entrapped to kill PC-9 cancer
cells.[270]
Besides, use of other photothermal agents such as GO[263]
and black phosphorus QD[271] has proved effective in hydrogel-
based release control. These include a GO-based hydrogel pre-
pared via noncovalent crosslinking of drug-coated GO and 𝛼-CD
(Figure 13B).[263] This hydrogel enabled codelivery of two drugs,
camptothecin and 5-FU, each loaded on the surface of GO by
irradiation at 808 nm. Encapsulation of black phosphorus QD
was also effective for photothermal hydrogel disassembly as vali-
dated by DOX release at 808 nm.[271] Using a conductive organic
polymer constitutes another approach for photothermal hydro-
gel disassembly. Sun et al. reported a DOX-loaded hydrogel pre-
pared with thiophene-incorporated conductive polymer. This hy-
drogel showed ability for photothermal activation, DOX release,
and ROS production at 915 nm.[272] Its triple modes of action was
consistent with the induction of high antitumor efficacy observed
in tumor grafted mice.
8.2.5. Porous Nanomaterial Loaded with Photothermal NP
While using mesoporous silica nanomaterials has played a
prominent role in the gating control, it is also being explored
in the design of photothermal disassembly systems. Li et al.
designed nano Au-encapsulated mSiO2 which was then used
for loading dsDNA oligonucleotides on its porous surface.[273]
This nanomaterial enabled NIR-triggered DNA release through
photothermal detachment, which was attributed to an elevated
temperature on the surface by heat produced from nano Au.
Besides nano Au, mSiO2 disassembly allows integration with
other photothermal agents such as iron oxide (Fe3O4) nanopar-
ticle (IONP)[274] and perylene diimide.[275] Lu et al. reported
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Figure 13. Therapeutic release by photothermal activation. A) NIR-controlled photothermal release of DNAzyme conjugated to gold nanoshell (AuNS)
for Zn ion detection in living cells. Reproduced with permission.[262] Copyright 2017, The Wiley & Sons. B) GO and 𝛼-CD-embedded hydrogel applied for
anticancer drug delivery via photothermal gel–sol transition by NIR light. Reproduced with permission.[263] Copyright 2016, Royal Society of Chemistry.
C) CuS-incorporated ZIF-8 MOF for NIR-triggered DOX delivery and photothermal therapy. Reproduced with permission.[264] Copyright 2016, Royal
Society of Chemistry. D) NIR-controlled photothermal rupture of GOmicrocapsules for DOX delivery. Reproduced with permission.[265] Copyright 2013,
Royal Society of Chemistry.
a silica nanocapsule loaded with DOX and IONP in its hol-
low cavity.[274] The encapsulated IONP enabled heat produc-
tion through magnetic field induction, which contributed to
nanocapsule disassembly for drug release. Yang et al. reported
a mesoporous organosilica nanocontainer loaded with SN38
and perylene diimide in its cavity.[275] NIR irradiation led to
its shell deformation, which contributed to drug release in the
tumor.
MOF-based nanocontainers also show growing potential in
the design of photothermal disassembly systems. Wang et al. re-
ported DOX-loaded ZIF-8 MOF, which was prepared by incor-
porating nano CuS as a photothermal agent into its lattice (Fig-
ure 13C).[264] Irradiation at 980 nm led to MOF disintegration,
which was positively correlated with the induction of cytotoxicity
inMCF-7 cells. Last, microscale capsules can serve as the delivery
container for photothermal disassembly. Kurapati and Raichur
reported dextran sulfate-doped microcapsules loaded with DOX
and modified with GO sheet on the surface (Figure 13D).[265]
Following irradiation at 1064 nm, these microcapsules ruptured
due to photothermal heating by GO, which contributed to DOX
release.
8.2.6. Photothermal Disassembly for Antibacterial Agent Release
Photothermal nanomaterials are effective in killing bacteria by
NIR-induced hyperthermia as studied with nano Au,[276] nano
Cu,[277] CuS[278] and rGO.[279] Such hyperthermia can engage
in photothermal disassembly for drug release. This is illus-
trated with the photothermal delivery of vancomycin, a glycopep-
tide class of antibiotics effective for treating Gram (+) bacterial
infections.[280,281] Wang et al. reported that AuNP immobilized
with vancomycin on its surface showed induction of a potent
bactericidal activity against drug-resistant bacteria at 808 nm.[282]
This effect was attributed to multiple modes of action that
comprise of cell wall-specific adsorption guided by vancomycin,
AuNP hyperthermia and hyperthermia-induced vancomycin re-
lease. Chitosan also contributes in bacteria-targeted delivery
due to its binding affinity to lipopolysaccharides and teichoic
acids present in the bacterial cell wall.[283,284] Thus the chitosan-
immobilized AuNR[283,285] was designed for the photothermal de-
livery of daptomycin.[283] This drug-loaded AuNR displayed abil-
ity for specific accumulation in an infection site, and following
irradiation at 808 nm, it induced a potent bactericidal activity
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due to hyperthermia-induced drug release.[283] Using an antibody
raised against a specific cell wall component constitutes another
promising approach for bacteria-targeted delivery as reported by
Meeker et al.[286] They designed Au nanocage immobilized with
an anti-staphylococcal protein A antibody and demonstrated a
dual capability for targeting and photothermal drug release as
applied to various antibiotic agents including daptomycin, van-
comycin or gentamycin.
Using polymer-based photothermal agents is effective in the
control of antibacterial disassembly as investigated with PDA[284]
and poly(pyrrole).[287] This involves a PDA/glycolchitosan hydro-
gel encapsulated with ciprofloxacin.[284] This chitosan-targeted
hydrogel showed a potent antibacterial efficacy against S. au-
reus in a mouse infection model at 808 nm.[284] Poly(pyrrole)
plays a similar role in photothermal disassembly as employed
in a hollow microsphere co-encapsulated with vancomycin.[287]
This drug-loaded microsphere showed a faster vancomycin
release, which occurred at 808 nm due to hyperthermia-
enhanced shell porosity, and it proved high bactericidal efficacy in
abscesses.
In section summary, photothermal activation constitutes a
core strategy that has been employed in various release systems
via gating and disassembly. A variety of photothermal agents have
been explored for this purpose that includeNIR dyes,[252–254] nano
Au,[70,92,288] HAuNS,[75,79] [83,84,247] AuNC,[78,79] carbon dots,[249]
black phosphorousQD,[251] and conductive polymers,[284,287] each
responsive to Vis–NIR stimulation (500–1000 nm). Application of
this photothermal strategy has resulted in promising results in
the area of anticancer and antibacterial therapy as summarized
in Table 4.
9. Therapeutic Release via Photodynamic
Activation
9.1. Photodynamic Delivery for Anticancer Therapeutics
9.1.1. Oxidative Linker Cleavage
ROS is associated with a high chemical reactivity that makes it
engage in linker cleavage for payload release. The linkers known
to be susceptible for ROS cleavage comprise of catechol,[289]
bis(alkylthio)ethene,[159] thioether,[290] and boronate.[291] They en-
gage in ROS-mediated release as illustrated with nano TiO2
chelated with 3,4-dihydroxybenzoic acid, which served as a linker
for hemoglobin attachment.[289] This nano TiO2 was able to re-
lease the protein in response to visible irradiation at >420 nm.
Its release was attributed to Ti–catechol bond cleavage that oc-
curred due to photoinduced electron transfer from TiO2 or by
phenol oxidation reaction with TiO2-produced
1O2. The ROS-
mediated linker cleavage occurs more frequently via sulfide ox-
idation. Lee et al. employed 1O2-sensitive bis(alkylthio)ethene
linker for payload (naphthalene dye) conjugation to the surface
of MSN which was pre-encapsulated with ZnPc within its pores
(Figure 14A).[159] Visible irradiation at 525 nm led to the dye
release, which was attributed to 1O2-triggered linker fragmen-
tation. Pei et al. applied this release approach for lipid vesicles
loaded with a paclitaxel homodimer tethered through thioether
along with tetraphenylchlorin photosensitizer.[290] Light irradia-
tion enabled these vesicles to produce 1O2 that contributed to
paclitaxel monomer release. Lastly, another ROS-responsive re-
lease involved a catechol–boronate linkage, which was used for
attaching anticancer bortezomib to crosslinked poly(dopamine)
polymers.[291] Irradiation at 635 nm enabled 1O2 production
which contributed to the drug release through oxidative cleavage
at its boronate linkage.
9.1.2. Oxidative Disassembly
Due to its short half-life, ROS restricts the scope of its oxida-
tive fragmentation to nearby molecules and objects at a close
proximity. These include nanocontainers that engage in its pro-
duction such as PS-encapsulated liposomes[292] and polymer
micelles.[32,117] Wang et al. demonstrated this approach using
tetraphenylporphyrin PS-loaded liposomes incorporated with 7-
dehydrocholesterol, an ROS-reactive cholesterol precursor.[292] Ir-
radiation at 420 nm produced 1O2 which contributed to vesi-
cle fragmentation and release of cytotoxic endoperoxides derived
from its reactions with 7-dehydrocholesterol. In another system,
ROS-mediated disassembly occurred in polymer micelles com-
posed of 9,10-dialkoxyanthracene-based amphiphilic molecules
as reported by Guo et al. (Figure 14B).[117] Irradiation at 525 nm
of these micelles which were encapsulated with eosin Y and an-
ticancer mitoxantrone resulted in the drug release via disassem-
bly. Brega et al. further defined the role of the alkoxyanthracene
linkage in the disassembly of DOX-loaded polymer micelles (Fig-
ure 14C).[32]
A drug linkage based on sulfur[115,116,293] or selenium[294] dis-
plays sufficient ROS reactivity for facile oxidation. This is il-
lustrated with thioether polymer micelles loaded with PS such
as chlorin e6 (Ce6)[115,116] and PPIX,[293] each applied in a de-
livery system for DOX[115,116] or SN38.[293] Their irradiation at
visible light (660 or 635 nm) resulted in drug release through
self-fragmentation, as illustrated by thioether reaction with 1O2
produced from Ce6 (Figure 14D).[115] Like sulfur in the chalo-
gen family, selenium is also reactive to 1O2, and applicable in
ROS-mediated disassembly. Pan et al. designed porphyrin-loaded
micelles made of di-selenide lipids.[294] These micelles showed
degradation under visible irradiation at 400 nm, leading to the
release of selenium byproducts which accounted for the induc-
tion of cytotoxicity in A549 cancer cells.
9.1.3. NIR Responsive Oxidative Disassembly
NIR irradiation is applicable in ROS production for photody-
namic disassembly. Ji et al. explored this approach using an NIR-
responsive indocyanine dye which has ability for producing sin-
glet oxygen.[295] They prepared 𝛼v𝛽3 integrin-targeted polymer
NP conjugated with camptothecin through the indocyanine. Fol-
lowing its irradiation at 660 nm, it showed a decrease in particle
size due to its oxidative fragmentation, which contributed to drug
release.
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Table 4. Therapeutic release via photothermal activation.
Release mode Nano delivery system Photothermal agent (Light, nm) Payload Refs.
Gating AuNR@mSiO2 Au (NIR) Naproxen
[243]
mSiO2@Au Au (808) Ibuprofen
[242]
AuNR@mSiO2 Au (543) DOX
[244]
UCN@mSiO2 Carbon dot (980) DOX, ZnPc
[249]
HAuNS Au (808) DOX, combretastatin A-4 phosphate, paclitaxel, cisplatin, siRNA [75,79] [83,84,247]
AuNC Au (808) DOX [78,79]
Disassembly Liposome AuNP (Vis) Berberine [250]
Liposome Black phosphorous (808) DOX [251]
Polymer micelle Cypate (NIR) Pt (IV) prodrug [252]
Polymer micelle Indocyanine (808) Cisplatin [254]
Polymer micelle Indocyanine (808) DOX [253]
Polymer micelle AuNR (808) DOX [257,258]
Polymer micelle AuNR, GO (808) DOX [260]
Polymer micelle PDA (808) DOX, NO [261]
Polymer micelle BODIPY (NIR) Camptothecin [255]
PDA-RGD AuNR, PDA (NIR) Cisplatin [259]
Polymer micelle AuNF (800) Rhodamine [266]
Polymer micelle Au (808) siRNA (GFP) [267]
AuNR@dsDNA AuNR (1064) Plasmid DNA [256]
AuNS@oligo Au (808) DNAzyme [262]
Hydrogel Indocyanine green (NIR) DOX [268]
Hydrogel AuNP (NIR) Bevacizumab [269]
Hydrogel Pt@dendrimer (NIR) Bortezomib [270]
Hydrogel GO (808) Camptothecin, 5-FU [263]
Hydrogel Black phosphorous (808) DOX [271]
Hydrogel Thiophene polymer (915) DOX [272]
Hydrogel-chitosan Poly(dopamine) (808) Ciprofloxacin [284]
Microsphere Poly(pyrrole) (808) Vancomycin [287]
Silica nanocapsule Fe3O4 (NIR) DOX
[274]
Silica nanocapsule AuNP (NIR) Rhodamine [245]
mSiO2@Au Au (NIR) dsDNA
[273]
Organosilica NP Perylene diimide (NIR) SN38 [275]
ZIF-8 MOF CuS (980) DOX [264]
CacO3 microcapsule GO (1064) DOX
[265]
AuNP@vancomycin Au (808) Vancomycin [282]
AuNR@chitosan Au (808) Daptomycin [283,285]
Au nanocage@antibody Au (NIR) Daptomycin, Vancomycin [286]
9.2. Photodynamic Delivery for Antibacterial Therapeutics
9.2.1. Nontargeted ROS Disassembly
ROS confers a broad spectrum of cytotoxicity against Gram(+)
and Gram(−) pathogens due to its general ability for induc-
ing membrane ruptures in bacterial pathogens.[296–298] Several
types of PS molecules have proven effective in ROS production
for antibacterial efficacy. These comprise of toluidine blue,[299]
curcumin,[300] RB,[64,86] PPIX,[98,142] and ZnPc.[301] Despite such
critical function, these PS molecules have poor solubility and
tend to aggregate in water. Therefore, PS delivery using a
nanocarrier should be beneficial as it allows to reduce their ag-
gregation and induce more bacterial uptake than free PS. These
benefits are illustrated by ROS-mediated disassembly of tolu-
idine blue encapsulated in lipid NP,[299] RB conjugated to an
exopolysaccharide nanocarrier,[302] or curcumin encapsulated in
poly(lactic acid) NP.[300] Visible irradiation of these PS-loaded
nanocarriers resulted in induction of potent bactericidal activity
against E. coli or S. aureus.
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Figure 14. Therapeutic release systems by 1O2-mediated photodynamic activation. A) Gating control in MSN via bis(alkylthio)ethene linker fragmen-
tation by 1O2 produced by encapsulated ZnPc. Reproduced with permission.
[159] Copyright 2013, Royal Society of Chemistry. B) Disassembly of 9,10-
dialkoxyanthracene-based supramolecular vesicles triggered by encapsulated eosin Y. Reproduced with permission.[117] Copyright 2016, Royal Society
of Chemistry. C) Disassembly of 9,10-dialkoxyanthracene-based polymer micelles designed for DOX release. Reproduced with permission.[32] Copy-
right 2019, American Chemical Society. D) Disassembly of Ce6 and DOX coloaded micelles via visible light-triggered 1O2 production for chemo and
photodynamic therapy. Reproduced with permission.[115] Copyright 2015, Royal Society of Chemistry.
9.2.2. Bacteria-Targeted ROS Disassembly
Targeted ROS delivery to bacterial cells is achieved using a system
with a targeting capability through its specific recognition and ad-
herence on the cell surface. This is illustrated with poly(fluorine-
benzothiadiazole) conductive polymer conjugated with a target-
ing ligand such as vancomycin for Gram(+) cells or PMB for
Gram(−) cells.[303] In this system, the polymer backbone itself
serves as PS for ROS production.[303] This polymer showed a po-
tent bactericidal activity against bacterial cells S. aureus and Psue-
domonas aeruginosa, which was induced only under white light ir-
radiation. This bacteria-targeted delivery was also achieved using
an antimicrobial peptide (YVLWKRKRKFCFI) which has a high
affinity to lipopolysaccharides. Thus, PPIX conjugated to this
peptide showed a greater antibacterial activity against Gram(−)
pathogens compared to PPIX alone.[304]
9.2.3. ROS Disassembly by Upconversion Luminescence
PS integration in UCN enables NIR-triggered ROS produc-
tion and disassembly.[64,86,305–307] This approach involves UCN
coated with a polymer layer made of poly(ethyleneimine),[308]
poly(vinylpyrrolidone)[301] or N-octyl chitosan,[309] and loaded PS
such as curcumin[308] or ZnPc[301,309] in its polymer shell layer.
NIR irradiation at 980 nm led to 1O2 production, which was
attributed to PS excitation and release by UCN luminescence
(432 nm). Such ROS delivery accounted for potent antibacterial
activity observed against multidrug-resistant bacterial pathogens
in vitro and in vivo infection models.
Min et al. reported another approach for PS loading using
UCN@mSiO2 for RB encapsulation in its porous shell layer.
[64,86]
At 980 nm irradiation, the RB-loaded UCN core emitted lumi-
nescence at 540 nm, which was effectively transferred for RB
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Table 5. Therapeutic release via photodynamic activation.
Release mode Delivery system (ROS reactive spacer) Photoactivation species (light, nm) Payload (ROS reactive linker) Refs.
Linker cleavage nano TiO2 TiO2 (420) Hemoglobin (Dihydroxybenzoate)
[289]
MSN (Alkylthioethene) ZnPc (525) Naphthalene dye [159]
Liposome Tetraphenylchlorin Paclitaxel (Thioether) [290]
Crosslinked polymer Poly(dopamine) (635) Bortezomib (Catechol–boronate) [291]
Disassembly Liposome (Dehydrocholesterol) Tetraphenylporphyrin (420) Dehydrocholesterol endoperoxide [292]
Polymer micelle (Alkoxyanthracene) Eosin Y (525) Mitoxantrone [117]
Polymer micelle (Alkoxyanthracene) Anthracene (365) DOX [32]
Polymer micelle (Thioether) Ce6 (660) DOX [115]
Polymer micelle (Propylene sulfide) Chlorin e6 (670) DOX [116]
Polymer micelle PPIX (635) SN38 (Thioether) [293]
Polymer micelle Porphyrin (400) Se (Diselenide) [294]
Polymer micelle Poly(fluorine-benzothiadiazole) (Vis) Vancomycin, PMB [303]
RGD-targeted polymer micelle Indocyanine (660) Camptothecin [295]
UCN@PEI Curcumin (432; 980) Curcumin [308]
UCN@mSiO2 UCN (980); RB (540) RB
[64,86]
UCN yolk–shell UCN (980); RB, hematoporphyrin (540) RB, hematoporphyrin [64]
UCN@Au/TiO2 UCN (980); TiO2 (NIR) Ampicillin
[310]
UCN@poly(vinylpyrrolidone) UCN (980); ZnPc ZnPc [301]
UCN@chitosan UCN (980); ZnPc ZnPc [309]
activation for ROS production and disassembly. This accounted
for a potent antibacterial activity against MRSA and extended
spectrum beta-lactamase-producing E. coli. In a continuing work,
they designed a hollow yolk–shell UCN loaded with two PS
types, RB embedded in its porous silica shell and hematopor-
phyrin methyl ether encapsulated in its yolk cavity.[64] Its lumi-
nescence enabled 1O2 production throughUCN-loaded PS activa-
tion, which led to effective killing of bacteria including antibiotic-
resistant MRSA and lactamase-producing E. coli. This ROS dis-
assembly system has further advanced to release an antibacterial
agent as reported by Xu et al.[310] They designed Au/TiO2-coated
UCN which was then loaded with ampicillin in its shell layer. Its
NIR excitation resulted in both ROS production and drug release
which enabled to kill ampicillin-resistant bacteria strains.
In section summary, photodynamic activation involves ROS
production catalyzed by photosensitizers or photoactive NPs. It
constitutes another core strategy that plays a critical role in PDT
and drug delivery.[28,34] Its applications have been explored in var-
ious ways in which payload release could be induced via linker
oxidation, oxidative gating, or disassembly. Photodynamic acti-
vation has made a significant impact on expanding the scope in
anticancer and antibacterial delivery systems as summarized in
Table 5.
10. Conclusions and Perspectives
Photoactivation allows therapeutic delivery to occur in an ac-
tively controlled manner within spatially well-defined cells and
tissues only. It opens a novel route for a non-invasive, spatiotem-
poral control of drug activation.[11] This strategy has been ap-
plied in numerous therapeutic areas including cancers and in-
fectious diseases, and it has made a significant impact on rapid
advances in the field of delivery applications as reviewed here
and elsewhere.[11,13,15,42] However, despite such promising results
and potential, its further development faces numerous technical
issues and challenges that pertain to intrinsic light properties,
its synthetic methods and its integration with an active targeting
strategy among others. These aspects are addressed briefly with
a focus on light limitations, drug conjugation methods, multiva-
lent ligand design,[5,8] and potential in clinical translation.
10.1. Light Limitation
Lights used in photoactivation strategies comprise of UV, vis,
and NIR, each offering a different set of properties in phototoxic-
ity, molecular absorptivity, tissue scattering, and penetration.[311]
Identifying an optimal light is critical in the successful appli-
cation of photoactivation systems. Irradiation at short wave-
length UV (UVC) is reported to cause DNA damages and consid-
ered cytotoxic.[312] However, irradiation in longer UV (medium,
long wavelength), visible and NIR range is generally well tol-
erable or non-toxic in mammalian cells[23,169,172] Light absorp-
tivity varies to a significant extent dependent on photocleav-
able linker types, PS molecules and photoactive NPs used. Long
wavelength UV light better enables linker photolysis for drug
release[11] than visible light which shows only limited effective-
ness via one or two-photon absorption.[11,124,127] However, visi-
ble light better fits in photodynamic activation because of its
stronger absorption by most PS molecules or NPs.[70,92,313] It
also shows lower light scattering than UV as the extent of light
scattering varies inversely proportional to the square of light
wavelength.[314] Both UV and visible light shows lower degree of
penetration with 100 µm (350–400 nm) and 150–750 µm (450–
700 nm)[315,316] compared to NIR light that penetrates as deep
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as 1200–2200 µm (800–1200 nm).[316] However, despite its high
tissue penetrability,[317–319] NIR irradiation carries a much lower
energy, and its direct use for photoactivation is limited only to a
few NPs including UCNs (808 nm, 980 nm).[86,98,104,110,142,320,321]
UCNs offer needed ability for UV–vis upconversion lumines-
cence by NIR excitation,[89,101,102,104–106,320] and they have shown
growing opportunities in the development of NIR-triggered re-
lease systems.[89,104,320]
10.2. Synthetic Method
Drug conjugation methods developed for photoactivation strate-
gies largely rely on covalent drug-nanocarrier conjugation
through a photocleavable linker. Numerous types of drug
molecules have been successfully applied for such conjugation
through amide,19, 81 carbamate,[169] ester,[126,140] triazole via azide-
alkyne click chemistry,[170] amine via N-alkylation,[172] and gold-
thiol chemisorption.[140] However, despite such broad applicabil-
ity, most of existing methods are still challenging to use because
they require a multi-step, divergent process. Recently, this has
drawn growing attention as illustrated with new synthetic ap-
proaches. Wong et al. addressed this issue by developing a TNB
linker[126] which provides important benefits such as synthetic
convenience (one step), multi-gram synthesis, and dual caging
arms.[169] They validated its synthetic convenience and capability
in the photocontrolled delivery of DOX conjugated in PAMAM
dendrimer. Dcona et al. employed a non-covalent approach in
lieu of a stable covalent bond.[171] They demonstrated the feasi-
bility of using electrostatic complexation in the loading of ONB-
caged DOX on the UCN surface.[171] Last, conjugation via azide-
alkyne click chemistry[170] offers a unique benefit by providing an
orthogonal approach that can occur under biological conditions
even in the presence of interfering functional moieties such as
amines and carboxylic acids.[170,171,182]
10.3. Active Targeting Strategy
The precision and efficiency in drug delivery can be greatly im-
proved by combining the photoactivated strategy with the ac-
tive targeting strategy. The latter is achieved by conjugating a
nanocarrier with a targeting ligand, aptamer or antibody to a
tumor or bacterial biomarker.[5,7,8] Of these, the multivalent lig-
and approach has proven effective in improving targeting speci-
ficity in a range of delivery systems.[5,7,8] However, this ligand tar-
geted approach has been applied only to a limited extent in a few
photoactivation systems. As reviewed here, these include ligand
conjugation with folate,[23,24,83,142,169,182,228] cyclic RGD[41,259] anti-
EGFR antibody,[74] or aptamer[76,211] in tumor-targeted systems,
and ligand conjugation with polymyxin,[172,303] chitosan,[283] an
amphiphilic peptide[304] or antibody[286] in bacteria-targeted sys-
tems. Integration of the two strategies, active ligand targeting
and photoactivation delivery, remains unexplored in most other
biomarkers in cancers. Besides FAR[9,322,323] and 𝛼v𝛽3 integrin
receptor,[324–326] each reported here, there are other promising
biomarkers applicable such as prostate-specific membrane anti-
gen receptor,[327] Her2,[328] riboflavin receptor,[329,330] and trans-
ferrin receptor.[10] Given recent advances in new synthetic meth-
ods on ligand conjugation, it would be increasingly feasible to
integrate these two complementary strategies in a single delivery
system. Their integration would offer greater potential for im-
proved safety and efficacy than either strategy alone.
10.4. Prospect in Clinical Translation
Photoactivated nanotherapeutic agents developed for clinical
therapies are mostly at an early stage[46,331] except verteporfin li-
posome (Visudyne), the PDT prototype approved for age-related
macular degeneration and further evaluated for locally advanced
pancreatic cancer (phase 2).[331,332] Their future development can
be considerably facilitated using insights fromdeveloped nanoth-
erapeutics and light therapies practiced in clinics. First, numer-
ous types of nanotherapeutic formulations have been approved
or advanced to clinical stages, in particular, in cancers.[333] These
include PEGylated liposome encapsulated with DOX (Doxil),[334]
heat-sensitive liposome loaded with DOX (ThermoDox),[335]
PLGA nanoparticles encapsulated with leuprolide (Eligard),[336]
albumin nanoparticles bound with paclitaxel (Abraxane),[337]
polyglutamate conjugated with paclitaxel (Opaxio),[338] and lipo-
somes encapsulated with mifamurtide (Mepact),[339] vincristine
(Marqibo),[340] or irinotecan (Onivyde).[341] However, in spite of
such success, the progression rates of nanotherapeutic candi-
dates toward regulatory approval show significant drops at the
efficacy stage as supported with phase 2 (48%) and phase 3 (14%)
compared to phase 1 (94%).[333] This is clearly indicative of poor
or lack of efficacy rather than toxicity, which could be attributable
to targeting and release control issues. Therefore, it would be pos-
sible to improve outcomes in efficacy through actively controlled
photoactivation in targeted tissues only.
Second, light therapies find more opportunities in topical and
superficial applications than systemic ones. This is illustrated
with nanoemulsion-based 5-aminolevulinic acid (BF-200),[342] a
topical agent being investigated for treating superficial basal cell
carcinomas such as actinic keratosis (phase 3) with laser irra-
diation at 632 nm.[343] Besides, recent advances in fiber optics
technology enable to induce photoactivation in deeper tissues.
For example, verteporfin was photoactivated for PDTwithin solid
pancreatic tumors by light delivered through a diffusing optical
catheter placed through a needle into the tumor tissue (phase
2).[332] In summary, clinical prospect of photoactivated nanoth-
erapeutics is growing conceivably in a range of therapeutic indi-
cations from anticancer treatments to antimicrobial procedures.
Acknowledgements
The author acknowledges support for cited works in part by the British
Council and Department for Business Innovation & Skills through the
Global Innovation Initiative (GII 207).
Conflict of Interest
The author declares no conflict of interest.
Adv. Therap. 2020, 3, 2000117 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2000117 (25 of 31)
www.advancedsciencenews.com www.advtherap.com
Keywords
linker photolysis, photodynamic reactions, photoisomerization, pho-
tothermal activation, therapeutic release, upconversion luminescence
Received: May 25, 2020
Revised: July 9, 2020
Published online: July 28, 2020
[1] Y. Lu, P. S. Low, Adv. Drug Delivery Rev. 2002, 54, 675.
[2] A. K. Patri, J. F. Kukowska-Latallo, J. R. Baker Jr, Adv. Drug Delivery
Rev. 2005, 57, 2203.
[3] N. Kamaly, Z. Xiao, P. M. Valencia, A. F. Radovic-Moreno, O. C.
Farokhzad, Chem. Soc. Rev. 2012, 41, 2971.
[4] H. Maeda, Adv. Enzyme Regul. 2001, 41, 189.
[5] M. Mammen, S. K. Choi, G. M. Whitesides, Angew. Chem., Int. Ed.
1998, 37, 2754.
[6] P. S. Low, W. A. Henne, D. D. Doorneweerd, Acc. Chem. Res. 2008,
41, 120.
[7] S. Bhatia, L. C. Camacho, R. Haag, J. Am. Chem. Soc. 2016, 138,
8654.
[8] L. L. Kiessling, J. E. Gestwicki, L. E. Strong, Angew. Chem., Int. Ed.
2006, 45, 2348.
[9] P. S. Low, S. A. Kularatne, Curr. Opin. Chem. Biol. 2009, 13, 256.
[10] Z. M. Qian, H. Li, H. Sun, K. Ho, Pharmacol. Rev. 2002, 54, 561.
[11] P. T. Wong, S. K. Choi, Chem. Rev. 2015, 115, 3388.
[12] J. Zhuang, M. R. Gordon, J. Ventura, L. Li, S. Thayumanavan, Chem.
Soc. Rev. 2013, 42, 7421.
[13] R. Tong, D. S. Kohane, Wiley Interdiscip. Rev.: Nanomed.
Nanobiotechnol. 2012, 4, 638.
[14] N. Fomina, J. Sankaranarayanan, A. Almutairi, Adv. Drug Delivery
Rev. 2012, 64, 1005.
[15] C. Englert, I. Nischang, C. Bader, P. Borchers, J. Alex, M. Pröhl,
M. Hentschel, M. Hartlieb, A. Traeger, G. Pohnert, S. Schubert,
M. Gottschaldt, U. S. Schubert, Angew. Chem., Int. Ed. 2018, 57,
2479.
[16] Y. Liu, P. Bhattarai, Z. Dai, X. Chen, Chem. Soc. Rev. 2019, 48, 2053.
[17] C. Brieke, F. Rohrbach, A. Gottschalk, G. Mayer, A. Heckel, Angew.
Chem., Int. Ed. 2012, 51, 8446.
[18] P. Rai, S. Mallidi, X. Zheng, R. Rahmanzadeh, Y. Mir, S. Elrington, A.
Khurshid, T. Hasan, Adv. Drug Delivery Rev. 2010, 62, 1094.
[19] J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma,
B. W. Pogue, T. Hasan, Chem. Rev. 2010, 110, 2795.
[20] J. H. Kaplan, B. Forbush, J. F. Hoffman, Biochemistry 1978, 17, 1929.
[21] A. P. Billington, K. M. Walstrom, D. Ramesh, A. P. Guzikowski, B. K.
Carpenter, G. P. Hess, Biochemistry 1992, 31, 5500.
[22] P. Klán, T. Šolomek, C. G. Bochet, A. Blanc, R. Givens, M. Rubina, V.
Popik, A. Kostikov, J. Wirz, Chem. Rev. 2013, 113, 119.
[23] S. K. Choi, T. Thomas,M. Li, A. Kotlyar, A. Desai, J. R. Baker Jr, Chem.
Commun. 2010, 46, 2632.
[24] S. K. Choi, T. P. Thomas, M.-H. Li, A. Desai, A. Kotlyar, J. R. Baker,
Photochem. Photobiol. Sci. 2012, 11, 653.
[25] M. M. Lerch, M. J. Hansen, G. M. van Dam, W. Szymanski, B. L.
Feringa, Angew. Chem., Int. Ed. 2016, 55, 10978.
[26] M. Wegener, M. J. Hansen, A. J. M. Driessen, W. Szymanski, B. L.
Feringa, J. Am. Chem. Soc. 2017, 139, 17979.
[27] Y. Huang, R. Dong, X. Zhu, D. Yan, Soft Matter 2014, 10, 6121.
[28] W. Wu, X. Shao, J. Zhao, M. Wu, Adv. Sci. 2017, 4, 1700113.
[29] S. K. Choi, NanoImpact 2016, 3-4, 81.
[30] Q. Mu, G. Jiang, L. Chen, H. Zhou, D. Fourches, A. Tropsha, B. Yan,
Chem. Rev. 2014, 114, 7740.
[31] C. C. Winterbourn, Nat. Chem. Biol. 2008, 4, 278.
[32] V. Brega, F. Scaletti, X. Zhang, L.-S. Wang, P. Li, Q. Xu, V. M. Rotello,
S. W. Thomas, ACS Appl. Mater. Interfaces 2019, 11, 2814.
[33] N. Nishiyama, Y. Morimoto, W.-D. Jang, K. Kataoka, Adv. Drug De-
livery Rev. 2009, 61, 327.
[34] S. S. Lucky, K. C. Soo, Y. Zhang, Chem. Rev. 2015, 115, 1990.
[35] A. Moussaron, Z. Youssef, A. Ben-Mihoub, R. Vanderesse, C. Fro-
chot, S. Acherar, in Photonanotechnology for Therapeutics and Imag-
ing (Ed: S. K. Choi), Elsevier, Amsterdam 2020, pp. 105.
[36] L. Vigderman, E. R. Zubarev, Adv. Drug Delivery Rev. 2013, 65, 663.
[37] Y. Chen, C. Tan, H. Zhang, L. Wang, Chem. Soc. Rev. 2015, 44, 2681.
[38] Y. Shi, M. Liu, F. Deng, G. Zeng, Q. Wan, X. Zhang, Y. Wei, J. Mater.
Chem. B 2017, 5, 194.
[39] X. Wu, C.-M. Dong, in Photonanotechnology for Therapeutics and
Imaging (Ed: S. K. Choi), Elsevier, Amsterdam 2020, pp. 83.
[40] C. Zhang, D. Li, X. Shi, in Photonanotechnology for Therapeutics and
Imaging (Ed.: S. K. Choi), Elsevier, Amsterdam 2020, pp. 23–43.
[41] W. Lu, M. P. Melancon, C. Xiong, Q. Huang, A. Elliott, S. Song, R.
Zhang, L. G. Flores, J. G. Gelovani, L. V. Wang, G. Ku, R. J. Stafford,
C. Li, Cancer Res. 2011, 71, 6116.
[42] J. M. Silva, E. Silva, R. L. Reis, J. Controlled Release 2019, 298, 154.
[43] T. Dvir, M. R. Banghart, B. P. Timko, R. Langer, D. S. Kohane, Nano
Lett. 2010, 10, 250.
[44] B. P. Timko, T. Dvir, D. S. Kohane, Adv. Mater. 2010, 22, 4925.
[45] Q. Liu, C. Zhan, D. S. Kohane, Bioconjugate Chem. 2017, 28, 98.
[46] M. Karimi, P. Sahandi Zangabad, S. Baghaee-Ravari, M. Ghazadeh,
H. Mirshekari, M. R. Hamblin, J. Am. Chem. Soc. 2017, 139, 4584.
[47] M. J. Geisow, W. H. Evans, Exp. Cell Res. 1984, 150, 36.
[48] P. Chan, J. Lovríc, J. Warwicker, Proteomics 2006, 6, 3494.
[49] M. J. Geisow, Exp. Cell Res. 1984, 150, 29.
[50] R. P. Feazell, N. Nakayama-Ratchford, H. Dai, S. J. Lippard, J. Am.
Chem. Soc. 2007, 129, 8438.
[51] G. M. Dubowchik, M. A. Walker, Pharmacol. Ther. 1999, 83, 67.
[52] B. Huang, S. Tang, A. Desai, X.-M. Cheng, A. Kotlyar, A. V. D. Spek,
T. P. Thomas, J. R. Baker Jr, Bioorg. Med. Chem. Lett. 2009, 19, 5016.
[53] E. Gullotti, Y. Yeo,Mol. Pharmaceutics 2009, 6, 1041.
[54] L. M. Kaminskas, B. D. Kelly, V. M. McLeod, G. Sberna, B. J. Boyd,
D. J. Owen, C. J. H. Porter,Mol. Pharmaceutics 2011, 8, 338.
[55] L.M. Kaminskas, B. D. Kelly, V.M.McLeod, B. J. Boyd, G. Y. Krippner,
E. D. Williams, C. J. H. Porter,Mol. Pharmaceutics 2009, 6, 1190.
[56] A. Homma, H. Sato, A. Okamachi, T. Emura, T. Ishizawa, T. Kato, T.
Matsuura, S. Sato, T. Tamura, Y. Higuchi, T. Watanabe, H. Kitamura,
K. Asanuma, T. Yamazaki, M. Ikemi, H. Kitagawa, T. Morikawa, H.
Ikeya, K. Maeda, K. Takahashi, K. Nohmi, N. Izutani, M. Kanda, R.
Suzuki, Bioorg. Med. Chem. 2009, 17, 4647.
[57] S. Dhar, Z. Liu, J. r. Thomale, H. Dai, S. J. Lippard, J. Am. Chem. Soc.
2008, 130, 11467.
[58] D. P. Naughton, Adv. Drug Delivery Rev. 2001, 53, 229.
[59] H. H. W. Chen, I.-S. Song, A. Hossain, M.-K. Choi, Y. Yamane, Z. D.
Liang, J. Lu, L. Y.-H. Wu, Z. H. Siddik, L. W. J. Klomp, N. Savaraj, M.
T. Kuo,Mol. Pharmacol. 2008, 74, 697.
[60] I. Ojima, Acc. Chem. Res. 2008, 41, 108.
[61] J. M. Chan, L. Zhang, R. Tong, D. Ghosh, W. Gao, G. Liao, K. P. Yuet,
D. Gray, J.-W. Rhee, J. Cheng, G. Golomb, P. Libby, R. Langer, O. C.
Farokhzad, Proc. Natl. Acad. Sci. USA 2010, 107, 2213.
[62] X. Xue, Y. Zhao, L. Dai, X. Zhang, X. Hao, C. Zhang, S. Huo, J. Liu,
C. Liu, A. Kumar, W.-Q. Chen, G. Zou, X.-J. Liang, Adv. Mater. 2014,
26, 712.
[63] V. G. Deepagan, D. G. You, W. Um, H. Ko, S. Kwon, K. Y. Choi, G.-R.
Yi, J. Y. Lee, D. S. Lee, K. Kim, I. C. Kwon, J. H. Park,Nano Lett. 2016,
16, 6257.
[64] F. Xu, M. Hu, C. Liu, S. K. Choi, Biomater. Sci. 2017, 5, 678.
[65] J.-F. Gohy, Y. Zhao, Chem. Soc. Rev. 2013, 42, 7117.
[66] L. Cheng, C. Wang, L. Feng, K. Yang, Z. Liu, Chem. Rev. 2014, 114,
10869.
Adv. Therap. 2020, 3, 2000117 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2000117 (26 of 31)
www.advancedsciencenews.com www.advtherap.com
[67] V. Biju, Chem. Soc. Rev. 2014, 43, 744.
[68] N. L. Rosi, C. A. Mirkin, Chem. Rev. 2005, 105, 1547.
[69] Y. Xia, W. Li, C. M. Cobley, J. Chen, X. Xia, Q. Zhang, M. Yang, E. C.
Cho, P. K. Brown, Acc. Chem. Res. 2011, 44, 914.
[70] M.-C. Daniel, D. Astruc, Chem. Rev. 2004, 104, 293.
[71] H. Chen, L. Shao, Q. Li, J. Wang, Chem. Soc. Rev. 2013, 42, 2679.
[72] H. Cai, K. Li, J. Li, S. Wen, Q. Chen, M. Shen, L. Zheng, G. Zhang, X.
Shi, Small 2015, 11, 4584.
[73] D. Li, S. Wen, W. Sun, J. Zhang, D. Jin, C. Peng, M. Shen, X. Shi, ACS
Appl. Bio Mater. 2018, 1, 221.
[74] G. Ku, Q. Huang, X.Wen, J. Ye, D. Piwnica-Worms, C. Li, ACSOmega
2018, 3, 5888.
[75] J. Li, M. Zhou, F. Liu, C. Xiong,W.Wang, Q. Cao, X.Wen, J. D. Robert-
son, X. Ji, Y. A. Wang, S. Gupta, C. Li, Radiology 2016, 281, 427.
[76] N. Zhao, J. You, Z. Zeng, C. Li, Y. Zu, Small 2013, 9, 3477.
[77] J. You, G. Zhang, C. Li, ACS Nano 2010, 4, 1033.
[78] M. S. Yavuz, Y. Cheng, J. Chen, C. M. Cobley, Q. Zhang, M. Rycenga,
J. Xie, C. Kim, K. H. Song, A. G. Schwartz, L. V. Wang, Y. Xia, Nat.
Mater. 2009, 8, 935.
[79] C. M. Cobley, L. Au, J. Chen, Y. Xia, Expert Opin. Drug Delivery 2010,
7, 577.
[80] N. S. Abadeer, C. J. Murphy, J. Phys. Chem. C 2016, 120, 4691.
[81] M. A. Mackey, M. R. K. Ali, L. A. Austin, R. D. Near, M. A. El-Sayed,
J. Phys. Chem. B 2014, 118, 1319.
[82] L. Au, D. Zheng, F. Zhou, Z.-Y. Li, X. Li, Y. Xia, ACS Nano 2008, 2,
1645.
[83] C. Xiong, W. Lu, M. Zhou, X. Wen, C. Li, Cancer Nanotechnol. 2018,
9, 1.
[84] W. Lu, G. Zhang, R. Zhang, L. G. Flores, Q. Huang, J. G. Gelovani,
C. Li, Cancer Res. 2010, 70, 3177.
[85] W. Li, J. Yang, L. Luo, M. Jiang, B. Qin, H. Yin, C. Zhu, X. Yuan, J.
Zhang, Z. Luo, Y. Du, Q. Li, Y. Lou, Y. Qiu, J. You, Nat. Commun.
2019, 10, 3349.
[86] F. Xu, Y. Zhao, M. Hu, p. zhang, N. Kong, r. Liu, C. Liu, S. K. Choi,
Chem. Commun. 2018, 54, 9525.
[87] M. Dahl, Y. Liu, Y. Yin, Chem. Rev. 2014, 114, 9853.
[88] J. M. Anglada, M. Martins-Costa, J. S. Francisco, M. F. Ruiz-López,
Acc. Chem. Res. 2015, 48, 575.
[89] G. Chen, H. Qiu, P. N. Prasad, X. Chen, Chem. Rev. 2014, 114, 5161.
[90] R. Justin, S. Roman, D. Chen, K. Tao, X. Geng, R. T. Grant, S. Mac-
Neil, K. Sun, B. Chen, RSC Adv. 2015, 5, 51934.
[91] S. Barua, X. Geng, B. Chen, in Photonanotechnology for Therapeutics
and Imaging (Ed: S. K. Choi), Elsevier, Amsterdam 2020, pp. 45–81.
[92] D. Eder, Chem. Rev. 2010, 110, 1348.
[93] Q. Mu, D. L. Broughton, B. Yan, Nano Lett. 2009, 9, 4370.
[94] J. Zhou, Y. Yang, C.-Y. Zhang, Chem. Rev. 2015, 115, 11669.
[95] T. Daimon, Y. Nosaka, J. Phys. Chem. C 2007, 111, 4420.
[96] M. Buchalska, P. Labuz, L. Bujak, G. Szewczyk, T. Sarna, S. Mack-
owski, W. Macyk, Dalton Trans. 2013, 42, 9468.
[97] A. Amirshaghaghi, L. Yan, J.Miller, Y. Daniel, J. M. Stein, T.M. Busch,
Z. Cheng, A. Tsourkas, Sci. Rep. 2019, 9, 2613.
[98] D. Chen, R. Tao, K. Tao, B. Chen, S. K. Choi, Q. Tian, Y. Xu, G. Zhou,
K. Sun, Small 2017, 13, 1602053.
[99] B. Zhao, P. J. Bilski, Y.-Y. He, L. Feng, C. F. Chignell, Photochem. Pho-
tobiol. 2008, 84, 1215.
[100] S. Heer, K. Kömpe, H. U. Güdel, M. Haase, Adv. Mater. 2004, 16,
2102.
[101] X. Liu, C.-H. Yan, J. A. Capobianco, Chem. Soc. Rev. 2015, 44, 1299.
[102] M. Haase, H. Schäfer, Angew. Chem., Int. Ed. 2011, 50, 5808.
[103] O. S. Wolfbeis, Chem. Soc. Rev. 2015, 44, 4743.
[104] N. M. Idris, M. K. G. Jayakumar, A. Bansal, Y. Zhang, Chem. Soc. Rev.
2015, 44, 1449.
[105] F. Wang, X. Liu, Chem. Soc. Rev. 2009, 38, 976.
[106] K. Tao, K. Sun, in Photonanotechnology for Therapeutics and Imaging
(Ed: S. K. Choi), Elsevier, Amsterdam 2020, pp. 147–176.
[107] A. Alabugin, Photochem. Photobiol. 2019, 95, 722.
[108] M. Hu, W. Liu, in Photonanotechnology for Therapeutics and Imaging
(Ed: S. K. Choi), Elsevier, Amsterdam 2020, pp. 205–241.
[109] J. Jin, Y.-J. Gu, C. W.-Y. Man, J. Cheng, Z. Xu, Y. Zhang, H. Wang, V.
H.-Y. Lee, S. H. Cheng, W.-T. Wong, ACS Nano 2011, 5, 7838.
[110] Q. Tian, K. Tao, W. Li, K. Sun, J. Phys. Chem. C 2011, 115, 22886.
[111] J. Vuilleumier, G. Gaulier, R. De Matos, Y. Mugnier, G. Campargue,
J.-P. Wolf, L. Bonacina, S. Gerber-Lemaire, Helv. Chim. Acta 2020,
103, e1900251.
[112] D. Staedler, T. Magouroux, R. Hadji, C. Joulaud, J. Extermann, S.
Schwung, S. Passemard, C. Kasparian, G. Clarke, M. Gerrmann, R.
Le Dantec, Y. Mugnier, D. Rytz, D. Ciepielewski, C. Galez, S. Gerber-
Lemaire, L. Juillerat-Jeanneret, L. Bonacina, J.-P. Wolf, ACS Nano
2012, 6, 2542.
[113] M. J. Hansen, W. A. Velema, M. M. Lerch, W. Szymanski, B. L.
Feringa, Chem. Soc. Rev. 2015, 44, 3358.
[114] M. Bio, G. Nkepang, Y. You, Chem. Commun. 2012, 48, 6517.
[115] G. Saravanakumar, J. Lee, J. Kim, W. J. Kim, Chem. Commun. 2015,
51, 9995.
[116] K. Kim, C.-S. Lee, K. Na, Chem. Commun. 2016, 52, 2839.
[117] S. Guo, X. Liu, C. Yao, C. Lu, Q. Chen, X.-Y. Hu, L. Wang, Chem.
Commun. 2016, 52, 10751.
[118] Z. Liu, Q. Lin, Q. Huang, H. Liu, C. Bao, W. Zhang, X. Zhong, L. Zhu,
Chem. Commun. 2011, 47, 1482.
[119] N. G. Patil, N. B. Basutkar, A. V. Ambade, Chem. Commun. 2015, 51,
17708.
[120] C. Yao, P. Wang, X. Li, X. Hu, J. Hou, L. Wang, F. Zhang, Adv. Mater.
2016, 28, 9341.
[121] G. Mayer, A. Heckel, Angew. Chem., Int. Ed. 2006, 45, 4900.
[122] M. Goard, G. Aakalu, O. D. Fedoryak, C. Quinonez, J. St. Julien, S. J.
Poteet, E. M. Schuman, T. M. Dore, Chem. Biol. 2005, 12, 685.
[123] P. Neveu, I. Aujard, C. Benbrahim, T. Le Saux, J.-F. Allemand, S. Vriz,
D. Bensimon, L. Jullien, Angew. Chem., Int. Ed. 2008, 47, 3744.
[124] A. Momotake, N. Lindegger, E. Niggli, R. J. Barsotti, G. C. R. Ellis-
Davies, Nat. Methods 2006, 3, 35.
[125] I. Aujard, C. Benbrahim, M. Gouget, O. Ruel, J.-B. Baudin, P. Neveu,
L. Jullien, Chem. - Eur. J. 2006, 12, 6865.
[126] P. T. Wong, S. Tang, J. Cannon, J. Mukherjee, D. Isham, K. Gam, M.
Payne, S. A. Yanik, J. R. Baker, S. K. Choi, ChemBioChem 2017, 18,
126.
[127] T. Furuta, S. S. H. Wang, J. L. Dantzker, T. M. Dore, W. J. Bybee, E.
M. Callaway, W. Denk, R. Y. Tsien, Proc. Natl. Acad. Sci. USA 1999,
96, 1193.
[128] S. Tang, J. Cannon, K. Yang, M. F. Krummel, J. R. Baker, S. K. Choi,
J. Org. Chem. 2020, 85, 2945.
[129] A. P. Gorka, R. R. Nani, J. Zhu, S. Mackem, M. J. Schnermann, J. Am.
Chem. Soc. 2014, 136, 14153.
[130] R. R. Nani, A. P. Gorka, T. Nagaya, T. Yamamoto, J. Ivanic, H.
Kobayashi, M. J. Schnermann, ACS Cent. Sci. 2017, 3, 329.
[131] E. Janett, Y. Bernardinelli, D. Müller, C. G. Bochet, Bioconjugate
Chem. 2015, 26, 2408.
[132] R. Johnsson, J. G. Lackey, J. J. Bogojeski, M. J. Damha, Bioorg. Med.
Chem. Lett. 2011, 21, 3721.
[133] S. Kantevari, S. Passlick, H.-B. Kwon, M. T. Richers, B. L. Sabatini,
G. C. R. Ellis-Davies, ChemBioChem 2016, 17, 953.
[134] R. J. T. Mikkelsen, K. E. Grier, K. T. Mortensen, T. E. Nielsen, K.
Qvortrup, ACS Comb. Sci. 2018, 20, 377.
[135] F. M. Rossi, M. Margulis, C.-M. Tang, J. P. Y. Kao, J. Biol. Chem. 1997,
272, 32933.
[136] F. M. Rossi, J. P. Y. Kao, J. Biol. Chem. 1997, 272, 3266.
[137] L. Niu, K. R. Gee, K. Schaper, G. P. Hess,Biochemistry 1996, 35, 2030.
Adv. Therap. 2020, 3, 2000117 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2000117 (27 of 31)
www.advancedsciencenews.com www.advtherap.com
[138] S. K. Choi, M. Verma, J. Silpe, R. E. Moody, K. Tang, J. J. Hanson, J.
R. Baker Jr, Bioorg. Med. Chem. 2012, 20, 1281.
[139] M. A. Inlay, V. Choe, S. Bharathi, N. B. Fernhoff, J. R. Baker, I. L.
Weissman, S. K. Choi, Chem. Commun. 2013, 49, 4971.
[140] S. S. Agasti, A. Chompoosor, C.-C. You, P. Ghosh, C. K. Kim, V. M.
Rotello, J. Am. Chem. Soc. 2009, 131, 5728.
[141] P. T. Wong, E. W. Roberts, S. Tang, J. Mukherjee, J. Cannon, A. J.
Nip, K. Corbin, M. F. Krummel, S. K. Choi, ACS Chem. Biol. 2017,
12, 1001.
[142] P. T. Wong, D. Chen, S. Tang, S. Yanik, M. Payne, J. Mukherjee, A.
Coulter, K. Tang, K. Tao, K. Sun, J. R. Baker Jr, S. K. Choi, Small 2015,
11, 6078.
[143] M. Gaplovsky, Y. V. Il’ichev, Y. Kamdzhilov, S. V. Kombarova,M.Mac,
M. A. Schworer, J. Wirz, Photochem. Photobiol. Sci. 2005, 4, 33.
[144] Y. V. Il’ichev, M. A. Schwörer, J. Wirz, J. Am. Chem. Soc. 2004, 126,
4581.
[145] M. Wilcox, R. W. Viola, K. W. Johnson, A. P. Billington, B. K. Carpen-
ter, J. A. McCray, A. P. Guzikowski, G. P. Hess, J. Org. Chem. 1990,
55, 1585.
[146] R. K. Paradise, D. A. Lauffenburger, K. J. Van Vliet, PLoS One 2011,
6, e15746.
[147] S. K. Choi, in Photonanotechnology for Therapeutics and Imaging (Ed:
S. K. Choi), Elsevier, Amsterdam 2020, pp. 243–275.
[148] Y. M. Li, J. Shi, R. Cai, X. Chen, Z. F. Luo, Q. X. Guo, J. Photochem.
Photobiol., A 2010, 211, 129.
[149] T. Narumi, K. Miyata, A. Nii, K. Sato, N. Mase, T. Furuta, Org. Lett.
2018, 20, 4178.
[150] A.-L. K. Hennig, D. Deodato, N. Asad, C. Herbivo, T. M. Dore, J. Org.
Chem. 2020, 85, 726.
[151] N. Asad, D. Deodato, X. Lan, M. B. Widegren, D. L. Phillips, L. Du,
T. M. Dore, J. Am. Chem. Soc. 2017, 139, 12591.
[152] Y. Venkatesh, S. Nandi, M. Shee, B. Saha, A. Anoop, N. D. P. Singh,
Eur. J. Org. Chem. 2017, 2017, 6121.
[153] Y. Venkatesh, Y. Rajesh, S. Karthik, A. C. Chetan, M. Mandal, A. Jana,
N. D. P. Singh, J. Org. Chem. 2016, 81, 11168.
[154] R. G. Wylie, M. S. Shoichet, J. Mater. Chem. 2008, 18, 2716.
[155] C. Bao, G. Fan, Q. Lin, B. Li, S. Cheng, Q. Huang, L. Zhu, Org. Lett.
2012, 14, 572.
[156] K. R. Gee, L. Niu, K. Schaper, V. Jayaraman, G. P. Hess, Biochemistry
1999, 38, 3140.
[157] J. W. Walker, J. A. McCray, G. P. Hess, Biochemistry 1986, 25, 1799.
[158] K. Mitra, C. E. Lyons, M. C. T. Hartman, Angew. Chem., Int. Ed. 2018,
57, 10263.
[159] J. Lee, J. Park, K. Singha, W. J. Kim, Chem. Commun. 2013, 49, 1545.
[160] H. Yan, C. Teh, S. Sreejith, L. Zhu, A. Kwok, W. Fang, X. Ma, K. T.
Nguyen, V. Korzh, Y. Zhao, Angew. Chem., Int. Ed. 2012, 51, 8373.
[161] J. Liu, W. Bu, L. Pan, J. Shi, Angew. Chem., Int. Ed. 2013, 52, 4375.
[162] R. J. Mart, R. K. Allemann, Chem. Commun. 2016, 52, 12262.
[163] Q. Zhao, Y. Wang, Y. Yan, J. Huang, ACS Nano 2014, 8, 11341.
[164] Q. Yuan, Y. Zhang, T. Chen, D. Lu, Z. Zhao, X. Zhang, Z. Li, C.-H.
Yan, W. Tan, ACS Nano 2012, 6, 6337.
[165] A. Martinez-Cuezva, S. Valero-Moya, M. Alajarin, J. Berna, Chem.
Commun. 2015, 51, 14501.
[166] J. R. Schnell, H. J. Dyson, P. E. Wright, Annu. Rev. Biophys. Biomol.
Struct. 2004, 33, 119.
[167] M. H. N. Tattersall, B. Brown, E. Frei, Nature 1975, 253, 198.
[168] D. Farquhar, R. A. Newman, J. E. Zuckerman, B. S. Andersson, J.
Med. Chem. 1991, 34, 561.
[169] P. T.Wong, S. Tang, J. Cannon, D. Chen, R. Sun, J. Lee, J. Phan, K. Tao,
K. Sun, B. Chen, J. R. Baker, S. K. Choi, Bioconjugate Chem. 2017, 28,
3016.
[170] J. A. Johnson, Y. Y. Lu, A. O. Burts, Y.-H. Lim, M. G. Finn, J. T. Kober-
stein, N. J. Turro, D. A. Tirrell, R. H. Grubbs, J. Am. Chem. Soc. 2011,
133, 559.
[171] M. M. Dcona, Q. Yu, J. A. Capobianco, M. C. T. Hartman, Chem.
Commun. 2015, 51, 8477.
[172] P. Wong, S. Tang, J. Mukherjee, K. Tang, K. Gam, D. Isham, C.Murat,
R. Sun, J. R. Baker, S. K. Choi, Chem. Commun. 2016, 52, 10357.
[173] J. Xiang, X. Tong, F. Shi, Q. Yan, B. Yu, Y. Zhao, J. Mater. Chem. B
2018, 6, 3531.
[174] Y. Dai, H. Xiao, J. Liu, Q. Yuan, P. a. Ma, D. Yang, C. Li, Z. Cheng, Z.
Hou, P. Yang, J. Lin, J. Am. Chem. Soc. 2013, 135, 18920.
[175] S. Li, R. Liu, X. Jiang, Y. Qiu, X. Song, G. Huang, N. Fu, L. Lin, J.
Song, X. Chen, H. Yang, ACS Nano 2019, 13, 2103.
[176] Q. Jin, F. Mitschang, S. Agarwal, Biomacromolecules 2011, 12, 3684.
[177] M. Noguchi, M. Skwarczynski, H. Prakash, S. Hirota, T. Kimura, Y.
Hayashi, Y. Kiso, Bioorg. Med. Chem. 2008, 16, 5389.
[178] M. Skwarczynski, M. Noguchi, S. Hirota, Y. Sohma, T. Kimura, Y.
Hayashi, Y. Kiso, Bioorg. Med. Chem. Lett. 2006, 16, 4492.
[179] A. Z. Suzuki, R. Sekine, S. Takeda, R. Aikawa, Y. Shiraishi, T. Ham-
aguchi, H. Okuno, H. Tamamura, T. Furuta, Chem. Commun. 2018,
55, 451.
[180] R. A. Gropeanu, H. Baumann, S. Ritz, V. Mailänder, T. Surrey, A. del
Campo, PLoS One 2012, 7, e43657.
[181] C. Xu, H. Li, K. Zhang, D. W. Binzel, H. Yin, W. Chiu, P. Guo, Nano
Res. 2019, 12, 41.
[182] X. Hu, J. Tian, T. Liu, G. Zhang, S. Liu, Macromolecules 2013, 46,
6243.
[183] G. Yu, W. Yu, Z. Mao, C. Gao, F. Huang, Small 2015, 11, 919.
[184] L. Huang, Y. Zhao, H. Zhang, K. Huang, J. Yang, G. Han, Angew.
Chem., Int. Ed. 2017, 56, 14400.
[185] X. Li, J. Mu, F. Liu, E. W. P. Tan, B. Khezri, R. D. Webster, E. K. L.
Yeow, B. Xing, Bioconjugate Chem. 2015, 26, 955.
[186] H. Song, W. Li, R. Qi, L. Yan, X. Jing, M. Zheng, H. Xiao, Chem.
Commun. 2015, 51, 11493.
[187] H. Song, X. Kang, J. Sun, X. Jing, Z. Wang, L. Yan, R. Qi, M. Zheng,
Chem. Commun. 2016, 52, 2281.
[188] M. LeBel, Pharmacotherapy 1988, 8, 3.
[189] Y. Shi, V. X. Truong, K. Kulkarni, Y. Qu, G. P. Simon, R. L. Boyd, P. Perl-
mutter, T. Lithgow, J. S. Forsythe, J. Mater. Chem. B 2015, 3, 8771.
[190] P. T. Wong, S. Tang, K. Tang, A. Coulter, J. Mukherjee, K. Gam, J. R.
Baker, S. K. Choi, J. Mater. Chem. B 2015, 3, 1149.
[191] G. Han, C.-C. You, B.-J. Kim, R. S. Turingan, N. S. Forbes, C. T. Mar-
tin, V. M. Rotello, Angew. Chem., Int. Ed. 2006, 45, 3165.
[192] P. K. Brown, A. T. Qureshi, A. N. Moll, D. J. Hayes, W. T. Monroe,
ACS Nano 2013, 7, 2948.
[193] Y. Pan, J. Yang, X. Luan, X. Liu, X. Li, J. Yang, T. Huang, L. Sun, Y.
Wang, Y. Lin, Y. Song, Sci. Adv. 2019, 5, eaav7199.
[194] M. K. G. Jayakumar, A. Bansal, K. Huang, R. Yao, B. N. Li, Y. Zhang,
ACS Nano 2014, 8, 4848.
[195] A. Fraix, N. Kandoth, I. Manet, V. Cardile, A. C. E. Graziano, R. Gref,
S. Sortino, Chem. Commun. 2013, 49, 4459.
[196] C. Fowley, A. P. McHale, B. McCaughan, A. Fraix, S. Sortino, J. F.
Callan, Chem. Commun. 2015, 51, 81.
[197] H.-J. Xiang, L. An, W.-W. Tang, S.-P. Yang, J.-G. Liu, Chem. Commun.
2015, 51, 2555.
[198] M. Guo, H.-J. Xiang, Y. Wang, Q.-L. Zhang, L. An, S.-P. Yang, Y. Ma,
Y. Wang, J.-G. Liu, Chem. Commun. 2017, 53, 3253.
[199] A. E. Pierri, P.-J. Huang, J. V. Garcia, J. G. Stanfill, M. Chui, G. Wu,
N. Zheng, P. C. Ford, Chem. Commun. 2015, 51, 2072.
[200] W. Chen, M. Chen, Q. Zang, L. Wang, F. Tang, Y. Han, C. Yang, L.
Deng, Y.-N. Liu, Chem. Commun. 2015, 51, 9193.
[201] W. Chen, D. Ni, Z. T. Rosenkrans, T. Cao, W. Cai, Adv. Sci. 2019, 6,
1901724.
[202] C. Alvarez-Lorenzo, L. Bromberg, A. Concheiro, Photochem. Photo-
biol. 2009, 85, 848.
[203] F. Huang, W.-C. Liao, Y. S. Sohn, R. Nechushtai, C.-H. Lu, I. Willner,
J. Am. Chem. Soc. 2016, 138, 8936.
Adv. Therap. 2020, 3, 2000117 © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim2000117 (28 of 31)
www.advancedsciencenews.com www.advtherap.com
[204] B. Chandra, S. Mallik, D. K. Srivastava, Chem. Commun. 2005, 3021.
[205] F. Reeßing, M. C. A. Stuart, D. F. Samplonius, R. A. J. O. Dierckx,
B. L. Feringa, W. Helfrich, W. Szymanski, Chem. Commun. 2019, 55,
10784.
[206] H. Wu, J. Dong, C. Li, Y. Liu, N. Feng, L. Xu, X. Zhan, H. Yang, G.
Wang, Chem. Commun. 2013, 49, 3516.
[207] X. Zhao, M. Qi, S. Liang, K. Tian, T. Zhou, X. Jia, J. Li, P. Liu, ACS
Appl. Mater. Interfaces 2016, 8, 22127.
[208] Y. Li, Y. Qian, T. Liu, G. Zhang, S. Liu, Biomacromolecules 2012, 13,
3877.
[209] J. Yang, J.-I. Song, Q. Song, J. Y. Rho, E. D. H.Mansfield, S. C. L. Hall,
M. Sambrook, F. Huang, S. Perrier, Angew. Chem., Int. Ed. 2020, 59,
8860.
[210] F. Sun, P. Zhang, Y. Liu, C. Lu, Y. Qiu, H. Mu, J. Duan, Carbohydr.
Polym. 2019, 206, 309.
[211] L. Yang, H. Sun, Y. Liu, W. Hou, Y. Yang, R. Cai, C. Cui, P. Zhang, X.
Pan, X. Li, L. Li, B. S. Sumerlin, W. Tan, Angew. Chem., Int. Ed. 2018,
57, 17048.
[212] B. Yan, J.-C. Boyer, N. R. Branda, Y. Zhao, J. Am. Chem. Soc. 2011,
133, 19714.
[213] Z. Sun, G. Liu, J. Hu, S. Liu, Biomacromolecules 2018, 19, 2071.
[214] G. Pasparakis, T.Manouras,M. Vamvakaki, P. Argitis,Nat. Commun.
2014, 5, 3623.
[215] Y. Zhang, G. Lu, Y. Yu, H. Zhang, J. Gao, Z. Sun, Y. Lu, H. Zou, ACS
Appl. Bio Mater. 2019, 2, 495.
[216] H. Zhao, W. Hu, H. Ma, R. Jiang, Y. Tang, Y. Ji, X. Lu, B. Hou, W.
Deng, W. Huang, Q. Fan, Adv. Funct. Mater. 2017, 27, 1702592.
[217] Y. Abebe Alemayehu, B. Tewabe Gebeyehu, C.-C. Cheng, Biomacro-
molecules 2019, 20, 4535.
[218] J. Lai, X. Mu, Y. Xu, X. Wu, C. Wu, C. Li, J. Chen, Y. Zhao, Chem.
Commun. 2010, 46, 7370.
[219] A. Hernández-Montoto, M. Gorbe, A. Llopis-Lorente, J. M. Terrés,
R. Montes, R. Cao-Milán, B. Díaz de Greñu, M. Alfonso, M. Orzaez,
M. D. Marcos, R. Martínez-Máñez, F. Sancenón, Chem. Commun.
2019, 55, 9039.
[220] J. Xiang, F. Ge, B. Yu, Q. Yan, F. Shi, Y. Zhao, ACS Appl. Mater. Inter-
faces 2018, 10, 20790.
[221] N. Ž. Kneževíc, B. G. Trewyn, V. S. Y. Lin, Chem. Commun. 2011, 47,
2817.
[222] S. He, K. Krippes, S. Ritz, Z. Chen, A. Best, H.-J. Butt, V. Mailänder,
S. Wu, Chem. Commun. 2015, 51, 431.
[223] S. Alberti, G. J. A. A. Soler-Illia, O. Azzaroni, Chem. Commun. 2015,
51, 6050.
[224] D. Wang, S. Wu, Langmuir 2016, 32, 632.
[225] N.Ma,W.-J. Wang, S. Chen, X.-S. Wang, X.-Q. Wang, S.-B. Wang, J.-Y.
Zhu, S.-X. Cheng, X.-Z. Zhang, Chem. Commun. 2015, 51, 12970.
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